[STUDY_ID_REMOVED] 
 
 
Study ID: ITI-007-402 
 
 
Title:  A Phase 3, Randomized, Double -Blind, Placebo -Controlled, Multi- Center Study to Assess the 
Efficacy and Safety of ITI- 007 Adjunctive to Lithium or Valproate in the Treatment  of Patients  With  Major 
Depressive Epi[INVESTIGATOR_425775] I or II Disorder (Bipolar Depression)  
 
 
 
 
 
Protocol Amendment  Version 1. 5 Date: September 4 , 201 9 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
CLINICAL STUDY PROTOCOL  
ITI-007-402 
 
A Phase 3, Randomized, Double -Blind, Placebo-Controlled, Multi-C enter 
Study to Assess the Efficacy and Safety of ITI- 007 Adjunctive to Lithium 
or Valproate  in the Treatment of Patients with Major Depressive Epi[INVESTIGATOR_211370] I or Bipolar II Disorder (Bipolar D epression)  
 
Confidential 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
Version of Amended 
Protocol: Version 1.5 
Date of Amended  Protocol: [ADDRESS_537921] No.: 2018-002749-12 
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by [CONTACT_145121] -Cellular Therapi[INVESTIGATOR_014], Inc. 
(ITI) . The concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, written 
consent of I TI. 
The study will be conducted according to the International Council for  Harmonisation harmonised 
tripartite guideline E6(R1): Good Clinical Practice.  
  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537922] ood all sections of the protocol entitled “ A Phase 3, randomized, 
double-blind, placebo- controlled, multi- center study to assess the efficacy and safety of 
ITI-007 adjunctive to lithium or valproate  in the treatment of patients with major depressive 
epi[INVESTIGATOR_123128] I or bipolar II disorder (bipolar depression) ” and the 
accompanying associated Investigator’ s Brochure . 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Amended Protocol version 1.5, dated 04 September  2019, the 
International Council for Harmonisation harmonised tripartite guideline E6(R1): Good 
Clinical Practice and all applicable government regulations . I will not make changes to the 
protocol before consulting with ITI (the Sponsor) or implement protocol changes without 
independent ethi cs committee approval except to eliminate an immediate risk to patient s. I 
agree to administer study treatment only to patient s under my personal supervision or the 
supervision of a sub- investigator.  
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected . Patient  identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without prior authorization from the Sponsor. 
   
Signature [CONTACT_789]   [INVESTIGATOR_425776] -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537923] of Abbreviations ................................................................................................................29  
1 Introduction ......................................................................................................................32  
2 Study Objectives ...............................................................................................................35  
2.1 Primary Efficacy Objective  .....................................................................................35  
2.2 Key Secondary Efficacy Objective  .........................................................................35  
  
2.4 Safety Objectives  ....................................................................................................36  
  
  
3 Investigational Plan  ..........................................................................................................38  
3.1 Study Design  ...........................................................................................................38  
3.1.1  Rationale of Study Design .......................................................................39  
4 Patient Selection and Withdrawal Criteria  .......................................................................41  
4.1 Selection of Study Population .................................................................................41  
4.1.1  Inclusion Criteria  .....................................................................................41  
4.1.2  Exclusion Criteria  ....................................................................................43  
4.2 Withdrawal of Patients from the Study  ...................................................................49  
4.2.1  Reasons for Withdrawal/Discontinuation ................................................49  
4.2.2  Handling of Patient Withdrawals or Patient Discontinuation of Study 
Intervention ..............................................................................................50  
4.2.3  Replacements  ...........................................................................................51  
5 Study Treatments  ..............................................................................................................52  
5.1 Method of Assigning Patients to Treatment Groups ...............................................52  
5.2 Treatments Administered  ........................................................................................52  
  
5.4 Management of Clinical Supplies  ...........................................................................55  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537924], Weight, and Height Measurements  .............................65  
6.1.6  Hepatitis Screening  ..................................................................................66  
6.1.7  HIV Screening  .........................................................................................66  
6.1.8  Urine Drug and Alcohol Screening ..........................................................66  
6.1.9  Laboratory Assessments  ..........................................................................66  
6.1.10  Serum and Urine Pregnancy Tests ...........................................................66  
6.1.11  Structured Clinical Interview  ...................................................................67  
6.1.12  Bipolarity Index  .......................................................................................67  
6.1.13  C-VISA  ....................................................................................................68  
6.1.14  Columbia Suic ide Severity Rating Scale  .................................................68  
6.1.15  Young Mania Rating Scale ......................................................................69  
6.1.16  Clinical Global Impression Scale of Bipolar Illness –Severity of Illness .69 
6.1.17  Eligibility Adjudication ............................................................................70  
6.2 Efficacy Assessments and Procedures  ....................................................................70  
6.2.1  MADRS  ...................................................................................................70  
6.2.2  Clinical Global Impression of Bipolar Illness –Severity  ..........................71  
6.2.3  Sheehan Disability Scale  .........................................................................71  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 8 6.2.4  Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form
 .................................................................................................................71  
6.2.5  World Health Organization -5 Well -Being Index  .....................................72  
6.2.6  Neuroticism, Extraversion, and Openness to Experience- Five Factor 
Inventory ..................................................................................................72  
6.3 Patient Placebo -Response Training.........................................................................72  
6.4 Safety and Tolerability Assessments  .......................................................................72  
6.4.1  Adverse Events  ........................................................................................73  
6.4.2  Other Safety Assessments  ........................................................................80  
6.5 Safety Monitoring Committee  ................................................................................83  
6.6  
  
  
  
  
6.8 Pregnancy  ................................................................................................................85  
7 Statistical and Analytical Plan  ..........................................................................................86  
7.1 Analysis Endpoints .................................................................................................86  
7.1.1  Prim ary Efficacy Endpoints .....................................................................86  
  
  
7.1.4  Safety Endpoints  ......................................................................................87  
  
  
7.2 Sample Size Calculations  ........................................................................................88  
7.3 Analysis Sets  ...........................................................................................................89  
7.4 Description of Subgroups to be Analyzed ..............................................................90  
7.5 Statistical Analysis Methodology  ...........................................................................90  
7.5.1  Patient Disposition, Analysis of Demographics and Other Baseline Characteristics  ..........................................................................................91
 
7.5.2  Prior and Concomitant Medications ........................................................91  
7.5.3  Study Medication Exposure and Treatment Compliance ........................92  
7.5.4  Analysis of Primary Efficacy Endpoint ...................................................92  
7.5.5  Analysis of Key Secondary Efficacy Endpoint .......................................94  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537925] of the Study ..................................................................................99  
8.3 Patient Information and Consent  ............................................................................99  
9 Investigator’ s Obligations  ..............................................................................................[ADDRESS_537926] .......................................................................................................102  
9.5 Adherence to Protocol...........................................................................................102  
9.6 Adverse Events and Study Report Requirements .................................................103  
9.7 Investigator’ s Final Report  ...................................................................................103  
9.8 Records Retention  .................................................................................................103  
9.9 Publications ...........................................................................................................103  
10 Study Managem ent .........................................................................................................104  
10.1  Monitoring ............................................................................................................104  
10.1.1  External Data Monitoring Committee  ...................................................104  
10.1.2  Monitoring of the Study .........................................................................104  
10.1.3  Inspection of Records ............................................................................104  
10.2  Management of Protocol Amendments and Deviations........................................104  
10.2.1  Modification of the Protocol ..................................................................104  
10.2.2  Protocol Deviations................................................................................105  
10.3  Premature Termination or Suspension of Study ...................................................105  
10.4  Halting Rules  ........................................................................................................106  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537927] of Tables  
Table  5-1  Study Medication and Dosing Schedule ......................................................... 53  
Table  5-2  Tablet Composition  ......................................................................................... 54  
Table  5-3  Weekly Treatment Cards  ................................................................................. 55  
Table 5 -4 Permitted Zolpi[INVESTIGATOR_425777] ....................................................... 59  
Table  6-1  Schedule of Events .......................................................................................... 61  
Table  6-2  Causality Categories  ....................................................................................... 76  
Table  6-3  Intensity Categories  ........................................................................................ 77  
Table 6-4  Number and V olume of Blood Samples .......................................................... 85  
 
  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402 04 September 2019  
Page 11 Protocol Synopsis  
Protocol Number:  
Title:  
Sponso r: 
Study Phase:  
Study Sites:  
Indication:  
Rationale:  ITI-007-[ADDRESS_537928] acebo- controlled, 
multi- center s tudy t o assess t he efficacy and  safety of  ITI-007 
adjunctive to lithium or valproate in the  treatment  of patients w ith 
major depressive epi[INVESTIGATOR_123128] I or bipolar II 
disorder (bipolar depression) 
Intra -Cellular T herapi[INVESTIGATOR_014] , Inc. (ITI) 
Phase 3 
Approximately 93 study sites globally 
Major depressive epi[INVESTIGATOR_123128] I or bipolar II 
disorder (bipolar depression) 
Bipolar disorder is a serious psychiatric disorder associated with 
shifts in mood including manic or hypomanic epi[INVESTIGATOR_1841], depressed 
epi[INVESTIGATOR_1841], or mixed epi[INVESTIGATOR_1841]. Every year bipolar disorder affects 
approximately 2.6% of the [LOCATION_002] (US) population age 
[ADDRESS_537929] at dopamine  2 (D2) receptors 
in vivo, w ith
 mesolimbic/mesocortical selectivit y. ITI-007 also 
incre
ases the phos phorylation of the NR2B, or GluN2B, subunit of 
N-methyl -D-aspartat e channels i n extrastriatal dopa mine - rich brain
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 12 regions (eg, nucleus accumbens), and indirectly modulates 
glutamatergic (NDMA and AMPA) activity downstream from 
dopamine [ADDRESS_537930]- synaptic 
D2 antagonism that appears efficacious in bipolar disorder and other pharmacological properties that may confer better safety and tolerability than other D 2 antagonists. As a 5- hydroxytryptomine 
2A (5 -HT2A) receptor antagonist and serotonin reuptake inhibitor, 
ITI-[ADDRESS_537931] antidepressant efficacy with fewer side effects than selective serotonin reuptake inhibitors. ITI-007’ s 
indirect glutamatergic modulation in combin ation with serotonin 
reuptake inhibition predicts rapid-acting antidepressant response. Importantly, ITI -[ADDRESS_537932] 
been associated with side effects for other antipsychotic drugs approved for the treatment of bipolar depression. For example, ITI-007 shows relatively weak affinity for 5- HT2C and no 
measurable affinity for histamine 1 (H 1) or muscarinic cholinergic 
receptors, which predict favorable body weight and metabolic profile responses to the extent that these r eceptors mediate such 
effects.  
Nonclinical data suggest that ITI -[ADDRESS_537933] the potential to 
treat depression. Antidepressant -like activity of ITI -007 was 
measured using the social defeat (resident -intruder) mouse model. 
In this model, 1 mg/kg ITI -007, administered once daily 
intraperitoneally for 28 days, reversed the defeat behavior, consistent with antidepressant efficacy.  
Brain receptor target engagement was confirmed in healthy male volunteers in the ITI-007-003 positron emission tomography Phase 1 clinical study. ITI -007 rapi[INVESTIGATOR_143448], showed long-
lasting and dose- related occupancy, and was generally safe and 
well-tolerated. Cortical 5 HT 2A receptors were shown to be fully 
occupi[CONTACT_6811] 10- mg ITI-007 (>85% occupancy). A dose of 40- mg 
ITI-007 achieved up to 39% striatal D2 occupancy (average of 29%) and up to 31% striatal serotonin transporter (SERT) 
occupancy (average of 22%). Together, these data confirm a central mechanism for ITI -007 at dopaminergic and serotonergic brain 
targets. An additional PET study in patients with schizophrenia 
(ITI-007-008) demonstrated an average of approximately 40% striatal D [ADDRESS_537934] antipsychotic drugs. Relatively 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537935] antipsychotic drugs. 
Clinical data from 3 well -controlled studies in patients with 
schizophrenia (ITI-007-005, ITI-007- 301, and ITI -007-302) are 
consistent with respect to the pharmacological profile and prediction for antidepressant effects with favorable safety and tolerab ility. In these 3 studies, ITI-007 has been safely administered 
once daily for up to 42 days at doses ranging from 20 to 140 mg. Furthermore, the ITI-007 60 mg dose had a similar trajectory and magnitude of improvement in psychosis as demonstrated a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) t otal s core in all 3 studies, which was statistically 
significant at Day 28 compared with placebo in 2 of these studies (ITI-007-005 and ITI-007-301). In addition to improving psychotic symptoms, ITI -[ADDRESS_537936] shown 
that ITI -007, which has been administered to more than 1500 
individuals, is well tolerated across a dose range from 1 to 140 mg and administered once daily for up to 42 days with a safety profile similar to placebo. These clinical data together with the nonclinical data and the pharmacological profile support the development of ITI-007 for the treatment of bipolar depression. 
Objectives:  Primary Objective  
The primary objective of this study is to compare the efficacy of 2 doses of ITI-007 adjunctive to treatment with lithium or valproate, administered orally once daily, to that of placebo adjunctive to treatment with lithium or valproate  as measured by  [CONTACT_425811] 43 in the total score of the rater -administered 
Montgomery-Åsberg Depression Rating Sc ale (MADRS) in 
patients with bipolar depression. 
 Key Secondary Efficacy Objective  
The key secondary efficacy objective of this study is to compare the 
efficacy of 2 doses of ITI- 007 adjunctive to treatment with lithium 
or valproate, administered orally once daily to that of placebo adjunctive to lithium or valproate as measured by [CONTACT_425812] 43 in the Clinical Global Impression Scale -
Bipolar Version- Severity (CGI -BP-S)-Depression score in patients 
with bipolar depression. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537937] meet all of the following criteria to be enrolled in 
this study : 
1. Is capable of understanding the written informed consent, 
provides signed and witnessed written informed consent, and agrees to comply with protocol requirements; 
2. Is between the ages of 18 and 75 years, inclusive, at the start of 
screening  (both male and female patients are to be included); 
3. Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM- 5) criteria for Bipolar I or Bipolar II Disorder 
as confirmed by [CONTACT_9304]-approved expert site-based rater by a Structured Clinical Interview for DSM -5 
Disorders –Clinical Trials Version (SCID -5-CT) (US sites only) 
or by [CONTACT_203439] (MINI; non-US sites only) and meeting all of the following 6  criteria:  
a. The start of the current major depressive epi[INVESTIGATOR_1865] (MDE) is at 
least 2  weeks but no more than 6 months prior to the screening 
visit;  
b. Appropriate severity of illness, at least moderately ill, as 
measured by a rater -administered MADRS total score ≥20 and 
corresponding to CGI -BP-S-Depression score and CGI -BP-S 
Overall score each ≥ 4 at the screening and baseli ne visits;  
c. Sufficient history and/or independent report (such as family 
member or outside practitioner) verifying that the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning;  
d. A lifetime history of at least 1 bipolar manic epi[INVESTIGATOR_425778] (for Bipolar I) or hypomanic epi[INVESTIGATOR_1865] (for Bipolar II); 
e. A rater -administered YMRS total score of ≤12 at the screening 
and baseline visits. The presence of psychotic symptoms may result in an increased YMRS without evidence of mania/hypomania; therefore, a patient with a YMRS >12 AND  
psychotic symptoms may be included pending adjudication review for diagnostic certainty of the depressive epi[INVESTIGATOR_1865]; 
f. A minimum of 28 days of trea tment with either lithium (and 0.4 
to 1.5 mEq/L blood level at screening) or valproate (minimum 
25 µg/mL blood level at screening ) and inadequate therapeutic 
response of depressive symptoms (confirmed by [CONTACT_425813]).   A re-test of 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 17 lithium or valproate levels is not permitted; any patient who 
does not meet either of the two requirements must be screen -
failed.  
4. Has a body mass ind ex (BMI) of 18 to 35 kg/m2, inclusive. 
5. Either must agree to use highly effective methods of birth 
control (defined as those, alone or in combination, that result in 
a failure rate less than 1% per year when u sed consistently and 
correctly) for at least 2 weeks prior to randomization (starting with signing infor med consent) through to the end-of- study 
follow-up visit or must be of non-childbearing potential (defined as either permanently sterilized or, if female, post-menopausal; the latter is d efined as at least 1  year with no menses without an 
alternative medical explanation).  
6. In the opi[INVESTIGATOR_689], the patient is willing and able 
to comply with study requirements, study visits, and to return 
to the clinic for follow-up evaluations as specified by [CONTACT_12695]. 
 Patient Exclusion Criteria  
Patients meeting any of the following criteria will be excluded from the study: 
1. The patient experiences a decrease in the rater -administered 
MADRS total score of ≥25% between screening and baseline 
visits.  
2. In the opi[INVESTIGATOR_689], the patient has a significant 
risk for suicidal behavior during the course of his or her participation in the study or 
a. At screening, the patient scores “ yes” on Items 4 or 5 in the 
Suicidal Ideation section of the C- SSRS with reference to a 6 -
month period prior to screening; or 
b. At screening, the patient has had 1 or more suicidal attempts 
with reference to a 2 -year period prior to screening; or 
c. At the baseline visit, the patient scores “ yes” on Items  4 or 5 in 
the Suicidal Ideation section of the C- SSRS with reference to 
screening; or  
d. At screening or the baseline visit, scores ≥4 on Item  10 (suicidal 
thoughts) on the rater- administered MADRS; or  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537938] (US sites only) or by [CONTACT_417671] (MINI; non-US sites only), of a psychiatric diagnosis other than bipolar disorder, including: 
a. Schizophrenia or other psychotic disorder; 
b. Anxiety disorders such as panic disorder, general anxiety 
disorder, or post- traumatic stress disorder as a primary 
diagnosis (however, anxiety symptoms may be allowed, if secondary to bipolar disorder, provided these symptoms do not require current treatment);  
c. Eating disorder; 
d. Primary diagnosis of obsessive-compulsive disorder; 
e. Moderate or severe substance use disorder (including for 
cannabis, excluding for nicotine); 
f. Any other psychiatric condition (other than bipolar disorde r) 
that has been the main focus of treatment within 12 months of 
screening;  
5. Patients who have experienced hallucinations, delusions, or any 
other psychotic symptomatology in the current depressive epi[INVESTIGATOR_425779] t 
attributable to a primary DSM -5 diagnosis other than bipolar 
disorder as described in Exclusion Criterion 4. The presence of these symptoms should be reviewed with the Medical Monitor and adjudication team on a case -by-case basis prior to 
inclusion; 
6. The patient has been hospi[INVESTIGATOR_425780] I disorder within 30 days of screening; 
Note:  This criterion is included to ensure that any manic phase 
has completely resolved before enrollment in the study. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537939] 5 years or received more than 1  course of 
electroconvulsive therapy  during the patient’ s lifetime; 
8. The patient is considered a rapid cycler, as defined by [CONTACT_425814] [ADDRESS_537940] 2 months duration or by a switch to an epi[INVESTIGATOR_211379]. (Each MDE must have lasted at least [ADDRESS_537941] 4 days, as validated by a reliable informant) ; 
Note : This criterion is included to avoid spontaneous remission 
during participation in the study that might confound treatment results.  
9. The patient is considered treatment -resistant, defined as having 
a lifetime history of treatment resistance (no re mission) to ≥2 
treatments with Food and Drug Administration (FDA) -
approved medications for bipolar depression (lurasidone, quetiapi[INVESTIGATOR_050], or Symby[CONTACT_276200], depending on the region) at an adequate dose (per regulatory- approved label) for an adequate 
duration (at lea st 6 weeks);  
10. The patient is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study; 
11. The patient presents with a lifetime history of epi[INVESTIGATOR_002], seizure, or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma; 
12. The patient h as a positive test for drugs of abuse or alcohol test 
at the screening or baseline visits, or presents evidence of either withdrawal from, or acute intoxication with , cocaine, opi[INVESTIGATOR_858], 
(meth)  amphetamines, alcohol, barbiturates, or hallucinogens 
or similar compounds; 
Note : Previous occasional use of alcohol or cannabis (but not 
synthetic marijuana/K2/Spi[INVESTIGATOR_6125]) or prescribed psychotropic (e g, 
benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573]) is allowed as long as the level of use does not meet DSM- 5 criteria for any moderate or severe 
substance use disorder within the 12 months prior to screening 
and the use of alcohol or cannabis is not considered to be the 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 20 precipi[INVESTIGATOR_425781]; patients are required to abstain from alcohol and cannabis use during the study; 
13. The patient has used one of the following agents under the 
specified conditions: 
a. Lifetime exposure to ITI -007 (i e, for US sites only, 
participat ion in previous clinical study with ITI -007 as verified 
by [CONTACT_425815]) or who has had exposure to any investigational product within [ADDRESS_537942] 4 years in >[ADDRESS_537943] with a central nervous system indication; 
b. Any strong or moder ate cytochrome P450 3A4 inhibitor or 
inducer within 7 days prior to the baseline visit; 
c. Use of any short- acting anxiolytic medications within 1  week 
of the baseline visit or of long- acting anxiolytics within 5 half -
lives of the baseline visit; 
d. Drugs with known psychotropic properties or any non-psychotropic drugs with known or potentially significant central nervous system effects within the last 28 days or 5  half-
lives before the baseline visit, whichever is less, as reviewed by [CONTACT_1689], including, but not limited to: 
i. Sedative hypnotics (with the exception of zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], or lorazepam as needed, no more than [ADDRESS_537944] 2 weeks of the treatment period).  Note : If zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_425782], or lorazepam are not available in specific regions, 
another sedative hypnotic or benzodiazepi[INVESTIGATOR_425783]. Medications may not be used in combination to treat insomnia. 
ii. Central opi[INVESTIGATOR_74453]/antagonists including tramadol (Ultram);  
iii. Anticonvulsants except valproate; 
iv. Mood stabilizers except lithium or valproate, antipsychotics, antidepressants;  
v. Methotrexate;  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537945] 
including but not limited to mianserin, mirtazapi[INVESTIGATOR_050], 
nefazodone, cyproheptadine, pi[INVESTIGATOR_4256], or fluvoxamine; 
vii. Immunosuppressants; 
viii. Dietary supplements  and medical foods are excluded unless 
approved by [CONTACT_1689]. Daily multivitamin use is not excluded. 
14. The patient has abnormal laboratory values or clinical findings 
at screening that are judged clinically significant and confirmed upon re- test ([ADDRESS_537946] returned to within normal range), including, but not limited to:  
a. Aspartate aminotransferase (AST) >2.0 × upper limit of 
normal (ULN); 
b. Alanine aminotransferase (ALT) >2.0 × ULN ; 
c. Alkaline phosphatase >2.0 × ULN ; 
d. Gamma -glutamyl transpeptidase >2.0 × ULN  
e. Total bilirubin >1.5 × ULN ; 
f. Serum creatinine >1.5 × ULN ; 
g. Blood urea nitrogen >1.5 × ULN ; 
h. Thyroid -stimulating hormone (TSH) outside of the normal 
limits and clinically significant, as determined by [CONTACT_1275] . Free thyroxine levels may be measured if TSH  
level is abnormal. The patient  will be excluded if the free 
thyroxine level is clinically significant;  
i. Any other clinically significant abnormal laboratory result at the time of the screening  examination ; 
j. 12-lead ECG (in a supi[INVESTIGATOR_425784]) corrected QT interval using the Fridericia 
formula (QTcF) 450 ms for males and  females  and/or heart 
rate ≤50 beats per minute, or evidence of clinically significant bundle-branch block. If a patient meets the QTcF 
and/or heart rate exclusion criteria during the screening 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 22 period, repeat ECG testing will not be permit ted. 
Note:  If it is the opi[INVESTIGATOR_425785] a lower 
heart rate is physiological in a well-fit subject or due to 
stable concomitant medications, this will be reviewed and approved by [CONTACT_27216] a case by [CONTACT_413].  
Note : Medical co nditions that are stable with medication (e g, 
hypertension, high cholesterol, and hyperthyroidism) are allowed as long as the condition has been stable for at least [ADDRESS_537947] safe participation in the study in the opi[INVESTIGATOR_425786]. 
15. The patient has clinically significant cardiovascular ( including 
but not limited to uncontrolled angina, or history of a 
myocardial infarction within 3  months prior to screening, or 
history of a clinically significant cardiac arrhythmia including 
antipsychotic drug- induced corrected QT interval 
prolongation), endocrine (including poorly controlled diabetes defined as glycated hemoglobin A
1c [HbA 1c] >53  mmol/mol 
[7.0%] at screening with no re- test allowed for HbA 1c), hepatic, 
renal, pulmonary, gastrointestinal, neurological, malignancy (including any malignancy and/or chemotherapy within the 2 years prior to screening; malignancy more than [ADDRESS_537948] been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications; some malignanc ies, such as basal cell 
carcinoma, may not preclude participation and will be individually reviewed), pheochromocytoma, metabolic, psychiatric or other condition that might be detrimental to the patient if he or she participates in the study (in the opi[INVESTIGATOR_3078] n of 
the Investigator) ; 
16. The patient has a history of human immunodeficiency virus 
(HIV) infection or has HIV antibodies in blood at screening; 
17. The patient has a history of hepatitis B or hepatitis C infection (or is tested positive for hepatitis B surface antigen or hepatitis C antibodies) AND  at screening has evidence of active disease 
defined as elevated ALT, AST, or bilirubin levels as specified in 
Exclusion Criterion 14; 
18. The patient is an employee of the Investigator or study site , or 
immedi ate family (i e, spouse, parent, child, or sibling, whether 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 25 will be provided in dose cards c ontaining 2 strips of over -
encapsulated tablets , and patients will be instructed to take 
2 capsules (1 capsule from each strip) per dose along with their 
concomitant dose of lithium or valproate.  
Statistical Methods  
Sample Size:  Approximately 520 patients will be random ly assigned  in a 1:1:1 
ratio to 1 of the 3 treatment arms  (ITI-007 40 mg, ITI-007 60 mg, 
and placebo). Assuming a common drop-out rate of 15% and a common correlation of 0.7, the sample size of 173 patients per treatment group will provide approximately 90% statistical power for the effect size of 0.4 for the primary efficacy endpoint in the ITI-007 60 mg treatment group. .  
Analysis Sets:  The All Patients Enrolled (ENR) Set will contain all patients who 
signed the informed consent for this study. 
The All Patients Randomized (RND) Set will contain all patients 
who signed the informed consent and were randomized to study 
medication.  
The Intent- to Treat  (ITT)  Set will contain  all random ly assigned  
patients who received at least 1 dose of study medication  and who 
had a valid baseline (pre -dose) measurement and at least [ADDRESS_537949] 1  dose of study medication and who had a valid 
baseline (pre- dose) measurement MADRS total score.  
The Safety Set will be used for analysis of safety endpoints . The 
Safety Set will contain all patients who took at least 1 dose of study 
medication. All analyses using the Safety Set will classify  patients 
according to treatment actually received . 
The PK Set will contain all patients who received study medication,  
had a valid baseline (pre- dose) measurement, had at least [ADDRESS_537950] 1 PK 
sample collected and analyzed . 
 Patient Disposition, Demographics, and Other Baseline Data  
Patient disposition will be summarized by [CONTACT_1570], when applicable, and overall, and by [CONTACT_425816], including incidence of screening failure and incidence of treatment or study discontinuation and the corresponding reasons. 
Time to  
treatment discontinuation due to all reasons, AEs ( all, AEs 
associated with worsening of bipolar depression, and AEs not 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 26 associated with worsening of bipolar depression) , lack of efficacy, 
or due to any other reason of special interest will be evaluated u sing 
the Kaplan -Meier method . The Log -rank test will be used to 
compare the time to discontinuation between each treatment group 
and the placebo group. 
Demographic and baseline characteristics , including bipolar 
disorder diagnosis and baseline efficacy mea sures,  will be listed 
and summarized by [CONTACT_388157]. No inferential statistics will be presented.  
Prior and Concomitant Medications  
Prior, prior concomitant, concomitant, and post- treatment 
medications, defined by [CONTACT_425817], will be summarized by [CONTACT_425818].   
Additionally, the number and percent of patients receiving 
concomitant medications of special interest, such as lithium, 
valproate, zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], or lorazepam, and the total number of days on each medication  will be summarized by 
[CONTACT_425819], for each week during the 
On-Treatment Period , and for post treatment with ITI -007 
 Study Medication Exposure and Treatment Compliance  
Exposure to study medication and treatment compliance will be presented for the Safety Analysis and ITT Sets. Duration of exposure (days) and dosing compliance (%) will be calculated and summarized by [CONTACT_1570]. In addition, the number and percentag e of patients exposed to study medication will be 
presented by [CONTACT_425820]. 
 Analysis of the Primary Efficacy Endpoint  
The treatment  effect on the primary efficacy endpoint will be 
evaluated using a mixed -effect  model repeated measures  (MMRM) 
method. The model will include the change from baseline at each pre-specified time point in the rater -administered MADRS total 
score as the response variable and visit, treatment group, site (or pooled site), and the stratification variables  (first-line treatment 
[lithium or valproate ] and Bipolar D isorder type at S creening [ I or 
II]), and the interaction term for treatment group -by-visit as fixed 
effects, the baseline MADRS total score and the interaction term of baseline MADRS -by-visit as covariat es. An unstructured 
covariance matrix will be used to model the covariance of within-
patient scores. The Kenward -Roger approximation (Kenward and 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537951] of Abbreviations  
Abbreviation  Definition  
5-HT 2A 5-hydroxytryptomine 2A (receptor) 
AE adverse event  
AIMS  Abnormal Involuntary Movement Scale 
ALT alanine aminotransferase  
ANCOV A  analysis of covariance  
AR autoregressive 
ARH heterogeneous autoregressive 
AST  aspartate aminotransferase 
BARS  Barnes Akathisia Rating Scale  
BMI  body mass index  
BPI [INVESTIGATOR_425787]-BP-S Clinical Global Impression Scale  of Bipolar Illness  – Severity  of Illness  
CI confidence interval 
CRO  contract research organization  
C-SSRS  Columbia Suicide Severity Rating Scale  
C-VISATM Clinical Validation Inventory for Study Admission (Bracket)  
D2 dopamine 2 receptor  
DMC  Data Monitoring Committee  
DSM -5 Diagnostic and Statistical Manual, 5th Edition  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
FA0(q)  No Diagonal Factor Analytic  
FDA  Food and  Drug Administration  
GCP  Good Clinical Practice  
H1 histamine 1 (receptor) 
HbA 1c glycated hemoglobin A 1c 
HIV human immunodeficiency virus  
ICF informed consent form  
ICH International Council for Harmonisation  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537952]  model repeated measures  
NEO -FFI Neuroticism, Extraversion, and Openness to Experience -Five Factor 
Inventory 
PET positron emission tomography 
PK pharmacokinetic 
PP per-protocol 
Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form  
QTcB  corrected QT interval using the Bazett formula 
QTcF  corrected QT interval using the Fridericia formula  
SAE  serious adverse event  
SAP statistical analysis plan  
SAS Simpson Angus Scale  
SCID -5-CT Structured Clinical Interview for DSM -5 Disorders – Clinical Trials 
Version  
SDS Sheehan Disability Scale  
SERT  serotonin transporter 
SIGMA  Structured Interview Guide for the MADRS  
TEAE treatment -emergent adverse event  
TOEP  Toeplitz structure  
TOEPH  heterogeneous Toeplitz structure  
ULN  upper limit of normal 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 31 US [LOCATION_002]  
WHO-5 World Health Organization -5 Well-being Index  
YMRS  Young Mania Rating Scale 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 32 1 Introduction  
Bipolar disorder is a serious psychiatric disorder associated with shifts in mood including 
manic or hypomanic epi[INVESTIGATOR_1841], depressed epi[INVESTIGATOR_1841], or mixed epi[INVESTIGATOR_1841]. Bipolar I Disorder is defined by [CONTACT_425821][INVESTIGATOR_1841], whereas Bipolar II Disorder is defined by [CONTACT_425822], but both are often associated with major depressive epi[INVESTIGATOR_1841] (MDEs) . Bipolar 
disorder affects approximately 5.7 million adult Americans, or about 2.6% of the [LOCATION_002] ( US) population aged [ADDRESS_537953] longer, recur more often, and are associated with a worse 
prognosis than manic/hypomanic epi[INVESTIGATOR_1841]. Bipolar depression, the predominant presentation 
of bipolar disorder, remains a significantly underserved medical need, with only a few regulatory-approved treatment options available. 
Lithium and valproate have shown efficacy in treating the mania of bipolar disorder and are 
used as mood stabilizer monotherapy in first- line treatment for people with acute bipolar 
depression. However, monotherapy with mood stabilizers has been less effective in treating the depressive phase of the disease ( Van Lieshout, 2010).  Little evidence exists to guide 
adjunctive therapy  of bipolar disorder, where drugs could be added to the mood stabilizers to 
treat the depressive symptoms of the disease ( Loebel, 2014a ). Antidepressants are commonly 
used as adjunctive therapy for patients with bipolar disorder, although concerns exist regarding their efficacy and potential to induce manic switching or reduce cy cle length 
(Sidor, 2011; Vázquez, 2013).  Hence, a significant need exists for an adjunctive agent that  
can be combined with mood stabilizers in patients with bipolar depression ( Loebel, 2014a ). 
Intra -Cellular Therapi[INVESTIGATOR_014] (ITI) , the Sponsor, is developi[INVESTIGATOR_425788]-007, a new chemical entity, for 
the treatment of patient s with MDEs associated with bipolar I or bipolar II disorder (bipolar 
depression) and for the treatment of agitation associated with dementia, including Alzheimer ’s disease . ITI-007 is currently in Phase 3 clinical development in the US  for the 
treatment of schizophrenia. 
ITI-007 is a novel small molecule therapeutic agent d esigned specifically to combine 
serotonergic, dopaminergic, and glutamatergic modulation in a dose-dependent manner. 
ITI-007 is a potent serotonin 5-hydroxytryptomine 2A (5- HT
2A) receptor antagonist with 
mesolimbic/mesocortical selective modulation of phos phoprotein pathways downstream of 
dopamine receptors, serotonin reuptake inhibition, and indirect glutamatergic modulation 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 33 (Snyder,  2015). As a dopamine receptor protein phosphorylation modulator, ITI-[ADDRESS_537954] at 
dopamine D 2 receptors in vivo, with mesolimbic/mesocortical selectivity.  ITI-007 also 
increases  the phosphorylation of the NR2B, or GluN2B, subunit of N- methyl -D-aspartate 
channels in extrastriatal dopamine -rich brain regions ( eg, nucleus accumbens) , and indirectly 
modulates glutamatergic (NDMA and AMPA) activity downstream from dopamine 1 receptor 
activation . 
Evidence supports the use of D 2 receptor  antagonists in the treatment of bipolar disorder, 
including bipolar depression ( Young, 2013; Loebel, 2014a ; Loebel, 2014b), as both 
monotherapy and adjunctive therapy to mood stabilizers. The pharmacologic profile of ITI-[ADDRESS_537955] antidepressant efficacy with fewer side effects than selective 
serotonin reuptake inhibitors. ITI-007’ s indirect glutamatergic modulation in combination 
with serotonin reuptake inhibition predicts rapid- acting antidepressant response.  Importantly, 
ITI-[ADDRESS_537956] been associated with side effects for 
other antipsychotic drugs approved for the treatment of bipolar depression. For example, 
ITI-007 shows relatively weak affinity for 5- HT 2C and no measurable affinity for histamine 1 
(H1) or muscarinic cholinergic receptors, which predict favorable body weight and metabolic 
profile responses to the extent tha t these receptors mediate such effects.  Additional details of 
the pharmacologic profile of ITI -007 can be found in the Investigator’ s Brochure 
(June 2018). 
Nonclinical data suggest that ITI -[ADDRESS_537957] the potential to treat depression 
(Snyder,  2015).  Antidepressant- like activity of ITI -007 was measured using the social defeat 
(resident -intruder) mouse model. Mice exposed to repeated social defeat conditions display a 
reduced amount of time in contact [CONTACT_143471] -aggressive mice than normal controls. 
Such defeat behavior is reversed by [CONTACT_40328] (but not acute) treatment with clinically effective 
antidepressant drugs. In this model, 1 mg/kg ITI -007, administered once daily 
intraperitoneally for 28 days, reversed the defeat behavior, consistent with antidepressant 
efficacy.  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 34 Brain receptor target engagement was confirmed in healthy male volunteers in the 
ITI-007-003 positron emission tomography (PET) Phase 1 clinical study ( Davis, 2015).  
Positron emission tomography was used to determine dopamine D 2 receptor, serotonin 
transporter (SERT), and serotonin 5- HT 2A receptor occupancy in the brain at various time s 
following single dose oral ITI -007 administration. ITI-007 rapi[INVESTIGATOR_143448], 
showed long- lasting and dose -related occupancy, and was generally safe and well -tolerated.  
Cortical 5 -HT 2A receptors were shown to be fully occupi[CONTACT_6811] 10- mg ITI-007 (>85% 
occupancy).  A dose of 40- mg ITI-007 achieved  up to 39% striatal D 2 occupancy (average of 
29%) and up to 31% striatal SERT occupancy (average of 22%). Together, these data confirm 
a central mechanism for ITI -007 at dopaminergic and serotonergic brain targets. An 
additional PET study in patients with schizop hrenia (ITI -007-008) demonstrated an average 
of approximately 40% striatal D [ADDRESS_537958] antipsychotic drugs. 
Clinical data from 3 well -controlled studies in patients with schizophrenia (ITI-007-005, 
ITI-007- 301, and ITI -007-302) are consistent with respect to the pharmacological profile and 
prediction for antidepressant effects with favorable safety and tolerability.  In these 3 studies, 
ITI-007 has been safely administered once daily for up to 42 days at doses ranging from 20 to 140 mg. Furtherm ore, the ITI-007 60 mg dose had a similar trajectory and magnitude of 
improvement in psychosis as demonstrated a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score in all 3 studies, which was statistically significant a t Day 28 compared with placebo in 2 of these studies (ITI-007-005 and 
ITI-007-301). In addition to improving psychotic symptoms, ITI-[ADDRESS_537959] shown that ITI-007, which has been 
administered to more than 1500 individuals, is well tolerated across a dose range from 1 to 140 mg and administered once daily for up to 42 days with a safety profile similar to placebo.  
These clinical data together with the nonclinical data and the pharmacological prof ile support 
the development of ITI-007 for the treatment of bipolar depression. Details on the  profile of 
ITI-007 can be found in the ITI-007 Investigator’s Brochu re. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 35 2 Study Objectives  
 Primary Efficacy Objective 
The primary objective of this study i s to compare the efficacy of 2  doses of ITI-007 
adjunctive to treatment with lithium or valproate, administered orally once daily , to that of 
placebo  adjunctive to treatment with lithium or valproate as measured by [CONTACT_211405] 43 in the total score on the rater -administered Montgomery- Åsberg 
Depression Rating Scale (MADRS) in patient s with bipolar depression. 
 Key Secondary Efficacy  Objective  
The key secondary efficacy objective of this study is  to compare the efficacy of 2 doses of 
ITI-007 adjunctive to treatment with lithium or valproate , administered orally once daily to 
that of placebo adjunctive to lithium or valproate as measure d by [CONTACT_211394] 43 in the Clinical Global Impression Scale -Bipolar Version- Severity (CGI -BP-S)-
Depression score in patients with bipolar depression. 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 36  
 Safety  Objectives  
The safety objectives of this study are to determine the safety and tolerability of 2 doses of 
ITI-007 adjunctive to treatment with lithium or valproate via: 
• Incidence of adverse events ( AEs); 
• Physical examination and neurological findings ; 
As well as change from baseline in the following safety assessments: 
• Young Mania Rating Scale (YMRS); 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 37 • Columbia Suicide Severity Rating Scale (C -SSRS) ; 
• Abnormal Involuntary Movement Scale ( AIMS ); 
• Barnes Akathisia Rating Scale  (BARS) ; 
• Simpson Angus Scale  (SAS); 
• Clinical laboratory evaluations ; 
• Electrocardiograms (ECGs) ; 
• Vital sign  measurements . 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537960] had inadequate response to their depression 
symptoms  and are currently taking one of the mood stabilizers, lithium or valproate.  
The study consists of the following periods: screening  period, on- treatment  period, and safety 
follow-up period. 
Screening Period  (2 Weeks)  
Eligible patients will be evaluated during a Screening Period up to 2 weeks in duration to 
ensure sufficient washout of prior and/or restricted medications. Extension of the Screening Period may be approved by [CONTACT_425823] a case- by-case basis.  
After obtaining written informed consent, diagnostic interviews  and physical exam ination s 
will be conducted, vital signs and ECGs will be assessed, and blood samples for laboratory assessments will be collected. Patient s considered potentially eligible for participation will be 
required to discontinue their current antidepressant treatment  and/or other psychotropic drugs 
and must remain on -treatment with  lithium or valproate for the duration of the study. 
 
 
 
 
At B aseline (Visit 2), patient s who continue to meet all eligibility criteria , including 
therapeutic levels of lithium or valproate, will be random ly assigned  to either adjunctive 
ITI-007 or placebo in 1 of the 3 treatment arms for a  6-week, double-blind treatment period. 
Patient s will be random ly assigned to one of the following groups in combination with 
lithium or valproate: 40- mg ITI-007, 60- mg ITI-007, or matching placebo . The rand om 
assignment will be stratified for both the first -line treatment (with lithium or valproate) and 
diagnosis at screening ( Bipolar I or B ipolar II D isorder).  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 39 Double-blind On -treatment Period (6 Weeks)  
Patient s will take their first dose of study medication  the evening of their baseline visit. A 
single dose will be taken each day in the evening for the duration of the on- treatment period.  
Following randomization, patient s will attend the clinic at Days 8, 15, 22, 29, 36, and 43. 
The on- study t reatment period will be a total of 6 weeks.  
Safety Follow -up Period (2 Weeks)  
A return to the clinic for a safety follow -up visit will occur at Week 8, approximately [ADDRESS_537961] dose of study medication . If possible, patient s who withdraw prematurely 
will be seen for an early termination visit (within 1 week of early termination , when  possible)  
and will be asked to return to the clinic for a safety follow -up visit 2 weeks following 
withdrawal . 
3.1.1 Rationale of Study Design   
The screening phase permits evaluation of the laboratory and ECG assessments and enables 
confirmation of eligibility for inclusion into the study. The screening phase will be no longer than 14 days , unless confirmed by [CONTACT_425824] a longer scr eening phase, not to 
exceed 28 days, is appropriate either to ensure washout of excluded medication with long 
half-life (e g, fluoxetine), under the supervision of the Investigator before baseline or to 
ensure minimum exposure of at least [ADDRESS_537962] abilizer (lithium or valproate ) that is 
required to have been started by [CONTACT_425825], under standard of care, before 
the start of screening. Patients  will be random ly assigned to 1 of 3 treatment groups (1:1:1) at 
the baseline visit and will receive treatment for up to [ADDRESS_537963] -line treatment (lithium 
or valproate ) and with regards to bipolar disorder diagnosis at study entry. In order to ensure 
patient  safety , a mand atory [ADDRESS_537964] to follow -up. 
Two ITI -007 doses , as adjunctive therapy with the mood stabilizers , lithium or valproate, 
were selected to deliver full occupancy of the cortical 5- HT
2A receptors (>85% occupancy) at 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 40 both doses. Data from a human PET brain receptor occupancy study in healthy male 
volunteers indicates that  40-mg ITI-007 is associated with  up to 39% striatal D 2 receptor 
occupancy (average of 29%) and up to 31% striatal SE RT occupancy (average of 22%) while 
the 60-mg dose is projected to achieve up to 50% striatal D [ADDRESS_537965] been shown to be generally safe and well tolerated and enable an exploration of t he dose required to achieve efficacy in this patient 
population. 
The doses to be administered in the present study, ITI-007 40 mg  and ITI-007 60 mg, were 
shown to be generally well tolerated in prior studies with no evidence of a need for drug 
titration. T herefore, a fixed -dose design will be employed in this study. 
The placebo control group is needed to establish the efficacy of a new compound. 
The treatment duration of 6 weeks has been chosen because this is considered a n acceptable 
period to demonstrate efficacy in this patient population. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 41 4 Patient  Selection and Withdrawal Criteria  
 Selection of Study Population 
Approximately 520 patients (1 73 patients /arm) will be enrolled at  approximately [ADDRESS_537966] meet all of the following criteria to be enrolled in this study:  
1. Is capable of understanding the written informed consent, provides signed and 
witnessed written informed consent, and agrees to comply with protocol requirements. 
2. Is between the ages of 18 and 75 years , inclusive, at the start of screening  (both male 
and female patients  are to be included). 
3. Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM -5) 
criteria for Bipolar I or Bipolar II Disorder as  confirmed by [CONTACT_425826]-approved expert site- based rater  by a Structured Clinical In terview for 
DSM -5 Disorders – Clinical Trials Version  (SCID -5-CT) (US sites only) or by [CONTACT_182092] (MIN I; non-US sites only) an d meeting 
all of the following 6 criteria:  
a. The start of the current MDE is at least 2 weeks but no more than 6 months prior to the screening visit; 
b. Appropriate severity of illness, at least moderately ill, as measured by a rater-administered MADRS total score  ≥20 and corresponding to 
CGI-BP-S Depression and Overall scores each  ≥4 at the S creening and 
Baseline Visits; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 42 c. Sufficient history and/or independent report (such as family member or 
outside practitioner) verifying that the current MDE is causing clinically 
significant distress or impairment in social, occupational, or other important a reas of functioning; 
d.  A lifetime history of at least 1 bipolar manic epi[INVESTIGATOR_425789] (for 
Bipolar I) or hypomanic epi[INVESTIGATOR_1865] (for Bipolar II); 
e. A rater -administered YMRS total score of ≤ 12 at the screening and baseline 
visits . The presence of psychotic symptoms may result in an increased 
YMRS without evidence of mania/hypomania; therefore, a patient with a 
YMRS >12 AND psychotic symptoms may be included pending 
adjudication review for diagnostic certainty of the depressive epi[INVESTIGATOR_1865]; 
f. A minimum of  28 days of treatment with either lithium (and 0.4 to  
1.5 mEq/ L blood level at screening ) valproate ( minimum 25  µg/mL blood 
level at screening ) and inadequate therapeutic response of depressive 
symptoms (confirmed by [CONTACT_425827]) . A re-test of lithium or valproate levels is not permitted; any patient 
who does not meet either of the two requirements m ust be screen failed . 
4. Has a body mass index (BMI) of 18 to  35 kg/m
2, inclusive; 
5. Either must agree to  use highly effective methods of birth control (defined as those, 
alone or in combination, that result in a failure rate less than 1 % per year when used 
consistently and correctly) for at least 2 weeks  prior to randomization ( starting with 
signing informed consent) through to the end-of-s tudy follow-up visit or must be of 
nonchildbearing potential (defined as either permanently sterilized or , if female,  post-
menopausal; the latter is defined as at least 1 year with no menses without an 
alternative medical explanation) ; 
6. In the opi[INVESTIGATOR_689] , the patient is willing and able to comply with study 
requirements, study visits, and to return to the clinic for follow-up evaluations as 
specified by [CONTACT_760]. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 43 4.1.2 Exclusion Criteria 
Patient s meeting any of the following criteria will be excluded from the study:  
1. The patient experiences a decrease in the rater -admin istered  MADRS total score of 
≥ 25% between screening and baseline visits ; 
2. In the opi[INVESTIGATOR_689] , the patient has a significant risk for suicidal 
behavior during the course of his or her participation in the study or  
a. At screening , the patient scores “ yes” on Items 4 or 5 in the Suicidal Ideation 
section of the C- SSRS with reference to a 6-month period prior to screening ; or  
b. At screening , the patient has had 1 or more suicidal attempts with reference to 
a 2-year period prior to screening ; or  
c. At the baseline visit, the patient scores “ yes” on I tems  4 or 5 in the Suicidal 
Ideation section of the C- SSRS with reference to screening ; or 
d. At screening  or the baseline visit, scores ≥ 4 on I tem 10 (suicidal thoughts) on 
the rater -administere d MADRS;  or 
e. Considered to be an imminent danger to himself, herself, or others . 
3. The patient is pregnant or breast- feeding . Female patients of childbearing potential 
must have negative serum and urine pregnancy tests at screening . On Day [ADDRESS_537967] prior to 
study treatment administration ; 
4. The patient ha s a history within [ADDRESS_537968], (US sites only) or by [CONTACT_223151] (MINI; non-US sites only), of a psychiatric diagnosis other than bipolar disorder, including: 
a. Schizophrenia or other psychotic disorder; 
b. Anxiety disorders such as panic disorder , general anxiety disorder, or 
post- traumatic stress disorder as a primary diagnosis (however, anxiety 
symptoms  may be allowed, if secondary to bipolar disorder, provided these 
symptoms do not require current treatment) ; 
c. Eating disorder; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 44 d. Primary diagnosis of obsessive-compulsive disorder; 
e. Moderate or severe substance use disorder (including for cannabis, excluding 
for nicotine); 
f. Any other psychiatric condition (other than bipolar disorder) that has been the main focus of treatment within 12 months of screening ; 
5. Patient s who have experienced hallucinations, delusions, or any other psychotic 
symptomatology in  the curr ent depressive epi[INVESTIGATOR_425790] a primary DSM -5 diagnosis other than bipolar 
disorder as described in Exclusion Criterion  4. The presence of these symptoms should 
be reviewed with the Medical Monitor and adjudication team on a case- by-case basis 
prior to inclusion; 
6. The patient has been hospi[INVESTIGATOR_425791] I disorder within 30 days  of screening ; 
Note : This criterion is included to ensure that any manic phase has completely 
resolved before enrollment in the study. 
7. The patient has  received electroconvulsive therapy, vagal nerve stimulation, or 
repetitive trans -cranial magnetic stimulation within the last 5 years or received more 
than 1 course of electroconvulsive therapy  during the patient ’s lifetime ; 
8. The patient is considered a rapid cycler , defined by [CONTACT_56833] [ADDRESS_537969] 2  months 
duration or by a switch to an epi[INVESTIGATOR_211379] . (Each MDE must have 
lasted at least [ADDRESS_537970] 4 days, as validated by a reliable 
informant.); 
Note : This criterion is inclu ded to avoid spontaneous remission during participation in 
the study that might confound treatment results.  
9. The patient is considered treatment -resistant, defined as having a lifetime history of 
treatment resistance (no remission) to ≥ 2 treatments with Foo d and Drug 
Administration ( FDA )-approved medications for bipolar depression (lurasidone, 
quetiapi[INVESTIGATOR_050], or Symby[CONTACT_276200] , depending on the region) at an adequate dose (per regulatory-
approved label) for an adequate duration (at least 6 weeks) ; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 45 10. The patient is currently receiving formal cognitive or behavioral therapy, systematic 
psychotherapy, or plans to initiate such therapy during the study; 
11. The patient present s with a lifetime history of epi[INVESTIGATOR_002], seizure, or convulsion, or 
electroencephalogram  with clinically significant abnormalities, delirium, dementia, 
amnestic, or other cognitive disorder or significant brain trauma; 
12. The patient h as a positive test for drugs of abuse or alcohol test at the s creening  or 
baseline visits or presents evidence of either withdrawal from or acute intoxication 
with cocaine, opi[INVESTIGATOR_858], amphetamines  (including methamphetamine) , alcohol, 
barbiturates,  or hallucinogens or similar compounds; 
Note : Previous occasional use of alcohol or cannabis (but not synthetic 
marijuan a/K2/Spi[INVESTIGATOR_6125]) or prescribed psychotropic (eg, benzodiazepi[INVESTIGATOR_050], opi[INVESTIGATOR_2573]) is 
allowed as long as the level of use does not meet DSM- 5 criteria for any moderate or 
severe substance use disorder within the 12 months prior to screening  and the use of 
alcohol or cannabis is not considered to be the prec ipi[INVESTIGATOR_425792]; patients are required to abstain from 
alcohol and can nabis use during the study; 
13. The patient has used one of the following agents under the specified conditions: 
a. Lifetime exposure to ITI-007 (i e, for US sites only, participat ion in previous 
clinical study with ITI -007 as verified by [CONTACT_425815]) or who has had 
exposure to any investigational product within [ADDRESS_537971] 4 years in >[ADDRESS_537972] with a central nervous system indication; 
b. Any strong or moderate cytochrome P450 3A4 inhibitor or inducer within 
7 days prior to the baseline visit; 
c. Use of any short- acting anxiolytic medications within 1 week of the baseline 
visit or of long- acting anxiolytics within 5 half -lives of the baseline visit; 
d. Drugs with known psychotropic properties or any non-psychotropic drugs 
with known or potentially significant central nervous system effects within 
the last 28 days or 5 half- lives before the baseline visit, whichever is less,  as 
reviewed by [CONTACT_1689], including , but not limited to : 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 46 i. Sedative hypnotics (with the exception of zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], or 
lorazepam as needed , no more than [ADDRESS_537973] 2 weeks of the treatment period ); 
Note : If zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], or lorazepam are not available in 
specific regions, another sedative hypnotic or benzodiazepi[INVESTIGATOR_425783]. Medications may not be used in 
combination to treat insomnia ; 
ii. Central opi[INVESTIGATOR_74453]/antagonists including tramadol (Ultram) ; 
iii. Anticonvulsants except valproate; 
iv. Mood stabilizers except lithium or valproate, antipsychotics, antidepressants ; 
v. Methotrexate; 
vi. Any known 5- HT
2A receptor antagonist or inverse agonist including 
but not limited to mianserin, mirtazapi[INVESTIGATOR_050], nefazodone, cyproheptadine, pi[INVESTIGATOR_4256], or fluvoxamine; 
vii. Immunosuppressants; 
viii. Dietary supplements  and medical foods are excluded unles s approved 
by [CONTACT_1689]. Daily multivitamin use is not excluded.  
14. The patient  has abnormal laboratory values or clinical findings at screening  that are 
judged clinically significant and confirmed upon re- test ( [ADDRESS_537974] 
returned to within normal range) , including, but not limited to : 
a. Aspartate aminotransferase (AST) >2.0 × upper limit of normal (ULN); 
b. Alanine aminotransferase (ALT) >2.0 × ULN ; 
c. Alkaline phosphatase >2.0 × ULN ; 
d. Gamma -glutamyl transpeptidase >2.0 × ULN ; 
e. Total bilirubin >1.5 × ULN ; 
f. Serum creatinine >1.5 × ULN ; 
g. Blood urea nitrogen >1.5 × ULN ; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 47 h. Thyroid -stimulating hormone (TSH) outside of the normal limits and 
clinically significant , as determined by [CONTACT_737] . Free thyroxine levels 
may be measured if TSH  level is abnormal. The patient  will be excluded if 
the free thyroxine level is clinically significant;  
i. Any other clinically significant abnormal laboratory result at the time of the 
screening  examination ; 
j. 12-lead ECG (in a supi[INVESTIGATOR_425793]) 
corrected QT interval using the Fridericia formula ( QTcF ) > 450 ms for 
males or females  and/or heart rate ≤ 50 beats per minute, or evidence of 
clinically significant bundle -branch blocks. If a patient meets the QTcF 
and/or heart rate exclusion criteria during the screening period, repeat ECG 
testing will not be permitted . 
Note:  If it is the opi[INVESTIGATOR_2511] I nvestigator that a lower heart rate is 
physiological in a well-fit subject or due to stable concomitant medications, this will be reviewed and approved by [CONTACT_27216] a case- by-case 
basis.  
Note : medical conditions that are stable with medication  (eg, hypertension, high 
cholesterol, and hyperthyroidism) are allowed as long as the condition has been stable for at least [ADDRESS_537975] safe participation in 
the study in the opi[INVESTIGATOR_425794]. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 48 15. The p atient has clinically significant cardiovascular  (including but not limited to 
uncontrolled angina, or history of a myocardial infarction within 3 months prior to 
screening, or history of a clinically significant cardiac arrhythmia including antipsychotic drug-induced corrected QT interval  prolongation) , endocrine  (including 
poorly controlled diabe tes defined as glycated hemoglobin A
1c [HbA 1c] >53  mmol/mol 
[7.0%] at  screening  with no re- test allowed for HbA 1c), hepatic, renal, pulmonary, 
gastrointestinal, neurological, malignancy  (including any m alignancy and/or 
chemotherapy within the 2 years prior to screening ; malignancy more than [ADDRESS_537976] been local and without metastasis and/or recurrence, and 
if treated with chemotherapy, withou t nervous system complications; some 
malignancies, such as basal cell carcinoma, may not preclude participation and will be individually reviewed), pheochromocytoma, metabolic, psychiatric or other condition 
that might be detrimental to the patient if he or she participates in the study (in the 
opi[INVESTIGATOR_689]); 
16. The patient  has a history of human immunodeficiency virus ( HIV) infection or has  
HIV antibodies in blood at screening; 
17. The patient  has a histor y of h epatitis B or  hepatitis  C infection  (or is tested positive for 
hepatitis B surface antigen or hepatitis C antibodies) AND  at screening has evidence of 
active disease defined as elevated ALT, AST , or bilirubin levels as specified in 
Exclusion Criterion 14; 
18. The patient is  an employee of the Investigator or study site, or immediate family (ie, 
spouse, parent, child, or sibling, whether biological or legally adopted) of such employees, the Investigator , the Sponsor, or contract research organizations  (CROs)  
conducting the study; 
19. The patient  is unable to be safely discontinued from current antidepressant medication, 
mood stabilizers, anticholinergics, or other psychotropic medications (in the opi[INVESTIGATOR_689]) or unable to safely con tinue on current treatment with lithium or 
valproate; 
20. The patient is judged by [CONTACT_143476]. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 49 
 Withdrawal of Patients  from the Study  
The planned overall duration of the study for each patient is up to approximately 10 weeks  (9 
visits) : a screening phase of up to 2 weeks (exceptions may be given to allow for washout of 
previous medication with a long half-life, as reviewed and approved b y the Medical Monitor, 
but not to exceed 28 days), a treatment phase of [ADDRESS_537977] follow -up visit on Day 56. 
4.2.1 Reasons for Withdrawal /Discontinuation  
Patient s may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by [CONTACT_78760] . Every effort should be made 
to keep patient s in the study. The reasons for patient s not completing the study will be 
recorded . A patient  may be withdrawn from the study for any of the following reasons: 
1. Does not meet the protocol inclusion criteria or meets the protocol exclusion criteria ; 
2. Noncompliance with the protocol; 
3. A serious or intolerable AE that , in the Investigator’s opi[INVESTIGATOR_1649], requires withdrawal 
from the study; 
4. Laboratory safety assessments that reveal clinically significant hematological or 
biochemical changes from baseline values , or baseline laboratory safety assessments 
that are returned after randomization but reveal clinically significant hematological or biochemical changes from screening ; 
5. Symptoms or an intercurrent illness not consistent with the protocol requirements or that justify  withdrawal ; 
6. Lost to follow-up; 
7. Other  (eg, pregnancy, development of contraindications of use of study medication ); 
8.  The Investigator or Sponsor decides to discontinue the patient ’s participation in the 
study; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537978] be 
questioned by [CONTACT_425828], lack of efficacy, personal or family reasons, or whether the patient withdrew 
consent and refused all end-of-study procedures, including refusing to give a reason; 
these reasons must be documented in the case report form; 
The Investigator will also withdraw a patient  if Sponsor terminates the study . Upon 
occurrence of a serious or intolerable AE, the Investigator  will confe r with the Sponsor or 
Medical Monitor as the Sponsor’ s designee. If a patient  is discontinued because of an AE, the 
event will be followed until it is resolved , stabili zes, is determined to be non- clinically 
significant, or the patient  is lost to follow -up. Any patient  may withdraw his or her consent at 
any time.  
4.2.[ADDRESS_537979] of the Sponsor. 
Patient s who discontinue study treatment or active participation in the study will no longer 
receive study medication . When a patient  withdraws from the study, the reason(s) for 
withdrawal shall be recorded by [CONTACT_425829] ( eCRF) . Whenever possible, all patient s who discontinue study treatment or 
withdraw from the study prematurely will undergo all end -of-study assessments. Patient s 
who fail to return for final assessments will be contact[CONTACT_425830] (2 documented 
telephone calls followed by 1 registered letter) in an attempt to have them comply with the 
protocol. 
It is vital to obtain follow -up data on any patient  withdrawn as a result of  an AE or serious 
adverse event (SAE ). In every case, efforts must be made to undertake protocol- specified, 
safety, follow -up procedures. All data collected from all patients, including early 
withdrawals, will be used in the reporting and analysis of the study. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537980] some screening procedures waived by [CONTACT_27216] a case -by-case basis; any patient  who is rescreened more than 
28 days following the previous screening  (as defined by [CONTACT_425831]) will 
need to have all screening procedures repeated. In all cases, a new informed consent must be 
obtained for a rescreen. A patient may not be screened more than 2 times . 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 52 5 Study Treatments  
 Method of Assigning Patient s to Treatment Groups  
At B aseline (Visit 2), patient s who continue to meet all eligibility criteria , including 
therapeutic levels of lithium or valproate, will be random ly assigned  to one of the following 
groups in combination with lithium or valproate: 40- mg ITI-007, 60- mg ITI-007, or matching 
placebo. The on-study treatment period will be a total of 6 weeks.  
An interactive voice response system  (IVRS) /interactive web response system (IWRS) 
(English only) will be used to administer the randomization schedule. Unblinded biostatistics 
personnel not participating in the conduct of the study will generate a permuted block 
randomization schedule using SAS software version  9.2 or later (SAS Institute Inc, Cary, 
North Carolina) for IVRS/IWRS, which will link sequential patient randomization numbers 
to treatment codes. In the event that the blind needs to be broken because of a medical 
emergency, the Investigator may unblind an individual patient’ s treatment allocation 
(Section  5.6.1). The randomization schedule will be stratified based on both treatment with 
either lithium or valproate and Bipolar I or Bipolar II diagnosis at screening . 
The dose of mood stabilizer will be adjusted to maintain a serum level in the range of 0.4 to  1.5 mEq/L for lithium or minimum 25  µg/mL  for valproate throughout the study as 
clinically appropriate per Investigator judgment. 
Each patient will be assigned a randomization number, which will be separate from the 
patient identification  number. Once a randomization number has been allocated to a patient, 
it may not be assigned to another patient. 
The IVRS/IWRS will send visit notifications to the study site  personnel, confirming the 
patient data that were entered.  The IVRS/IWRS notifications should be filed securely at the 
study site . 
 Treatments Administered  
Patients will be assigned to receive either ITI -007 ( 40- or 60- mg doses) or placebo in 
combination with their standard of care l ithium or valproate. Study site personnel will receive 
a treatment card number from the IVRS/IWRS for each patient at each treatment dispensing 
clinic visit, to ensure that the correct investigational product is dispensed. Patients will self -
administer all doses orally, once daily , at home, in the evening for the duration of the on-
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 53 treatment period. Treatment will be administered with or without food in the evening, and  at 
approximately the same time each day  whe never possible. Treatments will be provided in 
dose cards containing 2 strips of over- encapsulated tablets (Section 5.4.1).  Patients will be 
instructed to take 2 capsules ( 1 capsule from each strip) per dose along with the ir 
concomitant dose of lithium or valproate. 
 Identity of Investigational Product 
ITI-007 will be supplied as 20- and 60- mg over -encapsulated tablets  (capsules)  (see 
Table  5-1).  
 
 
Table  5-1 Study Medication  and Dosing Schedule  
 
Each ITI -007 dosing container will be labeled according to local laws and regulations. 
The composition of the over- encapsulated tablets is listed in Table  5-2. Study Medication  Dosing Schedule  
40-mg ITI-007 2 over -encapsulated tablets of 20 -mg ITI -007 
Daily Dose: 40 -mg ITI-007 
60-mg ITI-007 2 over -encapsulated tablets: 1 over -encapsulated tablet  of 
60-mg ITI- 007 and 1 over- encapsulated tablet  of placebo  
Daily Dose: 60 -mg ITI-007 
Placebo  2 over -encapsulated tablets  of placebo  
Daily Dose:  0-mg ITI-007 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537981] the same excipi[INVESTIGATOR_425795]-007 but do not contain the active compound. 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537982] will contain a sufficient quantity for 1 patient 
for each week (7 doses, plus 1 extra) of the 6- week treatment period , to be distributed at 
weekly visits . Each ITI -[ADDRESS_537983] for each study treatment will contain two 1×8 strips of over- encapsulated 
tablets (final product in capsule form ) as described  in Table  5-3.  
Table  5-[ADDRESS_537984] Contents  
Placebo  Two 1×8 strips of placebo over -
encapsulated tablets  (8 over -encapsulated 
tablets/strip)  
 
60-mg ITI-007  One 1×8 strip of 60- mg ITI -007 over-
encapsulated tablets  (8 over -encapsulated 
tablets/strip );  
One 1×8 strip of placebo over- encapsulated 
tablets  (8 over- encapsulated tablets/strip ) 
 
40-mg ITI -007 Two 1×8 strips of 20 -mg ITI -007 over -
encapsulated tablets  (8 over -encapsulated 
tablets/strip)  
 
Note: Each card will hold [ADDRESS_537985] be stored in a secure area (eg , a locked cabinet)  while in storage at the 
study site , protected from moisture, and kept at a room temperature between 15°C and  30°C 
(59°F to  86°F). Patients will be instructed to store the weekly treatment card at room 
temperature at home, out of the reach of children . Patients will be instructed to take 
[ADDRESS_537986] to the study site at the next visit to assess compliance . 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537987] be promptly reported to the Medical Monitor. Overdoses without signs or symptoms do not need to be recorded as AEs; in case of any AEs associated with the overdose, these 
should be reported on relevant AE/SAE sections in the eCRF. 
5.5.[ADDRESS_537988] be carefully 
documented. These errors may include but are not limited to providing the wrong dose (not 
taking 2 capsules per dose, taking too many capsules per dose,), losing medication, or admini stration at the wrong time of day. Medication adherence will be emphasized at every 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537989] in 
order to minimize medication error. Additional adherence procedures may be i mplemented.  
5.5.3 Treatment of Medication Errors  
The treatment of medication errors should be discussed with the Medical Monitor  on a 
case- by-case basis. In the case of overdose, see Section 5.5.1. 
 Blinding  
The study will be performed in a double-blind manner. All study medication  will be supplied 
in identical treatment cards and packaging, and will be similar in color, smell, taste, and 
appearance, thereby [CONTACT_211412]-blind conditions. 
5.6.1 Breaking the Blind  
A patient ’s treatment assignment  will not be broken until the end of the study unless medical 
treatment of the patient depends on knowing the study treatment the patient  received . In the 
event that the b lind needs to be broken because of a medical emergency, the Investigator may 
unblind an individual patient ’s treatment allocation . As soon as possible, the Investigator 
should first contact [CONTACT_425832] n for 
revealing the actual treatment received by [CONTACT_90323]. The treatment assignment will b e 
unblinded through IVRS/IWRS. Reasons for treatment unblinding must be clearly explained 
and justified in the eCRF . The date on which the code was broken togethe r with the identity 
of the person responsible must also be documented. 
Any patients whose treatment assignment is unblinded will discontinue the study. 
The overall randomization code will be broken only for study reporting purposes. This will 
occur once all final clinical data have been entered into the database and all data queries have 
been resolved.  
 Treatment Compliance  
Patient  compliance will be assessed by [CONTACT_425833]-blind treatment phase ( Table  6-1). Any irregularities in medication 
adherence should be discussed with the patient. Any patient who misses 2 doses of study 
medication  per week in any 2 weeks of the study treatment period or who misses 3 or more 
doses of study medication  in any single week s hould be considered for early discontinuation. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537990] be car efully 
documente d. These errors may incl ude, but  are no t limited to, pr ovi ding the wrong dose (not 
taking 1 capsule per dose or taking too many capsules per dose), losing medication, or 
administration  at the wr ong  time of  day. Medication  adherence w ill be  emphasized a t every 
visit. Written ins tructions  will be  provided to the  patients w ith  the weekly medication  card in 
order to mi
nimize medication erro r. Additional adherence procedures may be implemented. 
 Prior and Concomitant Therapy  
Patients ar e required not to use the following during the study: alcohol, cannabis, any known 
5-HT 2A recept or antagonist or inverse agonist, a ny strong  or moderat e cytochrome P450 3A4 
inhi
bitor or inducer, any short- acting anx iolytic, o r any drugs with know n psychotropic 
properties, or any non-psychotropic drugs with potential central nervous system effects . The  
only exceptions are z olpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], and lorazepam , which may be taken no more 
than [ADDRESS_537991] 2 
weeks of the Treatment Period (Section 4.1.2, Exclusion C riterion 13) . Table 5-4 presents the 
permitted use of zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], a nd lorazepam. If zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], o r 
lorazepam are not available in specific regions, another sedative hypnotic or benzodiazepi[INVESTIGATOR_425796] .
Medications may not be used in combination to treat insomnia. If a p atient is not  able to 
disconti
nue use of zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], or lorazepam (or equivalent) by [CONTACT_425834] [ADDRESS_537992] the  Sponsor or Sponsor’s 
representative to discuss the patient’s appropriateness to continue in the study. 
Page 58 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 59 Table 5-4 Permitted Zolpi[INVESTIGATOR_425797] 10  mg/day 
(bedtime)  Insomnia  During screening 
and first [ADDRESS_537993] 8 hours prior to any 
psychiatric 
assessments  Zolpi[INVESTIGATOR_425798] 12.5 mg/day 
(bedtime)  Insomnia 
Lorazepam  Up to 2mg/day Insomnia, 
agitation, anxiety  
Note: Zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], and lorazepam should be used sparingly and for symptoms severe enough to 
require treatment as per the Investigator ’s judgment.  Prophylactic use is not allowed.  If zolpi[INVESTIGATOR_6730], zolpi[INVESTIGATOR_216326], 
or lorazepam are not available regionally, then  an alternative sedative hypnotic or benzodiazepi[INVESTIGATOR_425799] . 
 
Patient s considered potentially eligible for participation will be required to discontinue their 
current antidepressant tr eatment and/or other psychotropic drugs for the duration of the study. 
Discontinuation of long-acting prohibited medications that require more than a 2- week 
washout should be discussed on a case- by-case basis with the Medical Monitor for approval 
of a longer screening phase to ensure washout of excluded medication with long er half-life 
(eg, fluoxetine) under the supervision of the Investigator before baseline.  
Use of all concomitant medications , including lithium and valproate,  will b e recorded in the 
patient ’s eCRF. As a minimum requirement, the drug name [CONTACT_425863] . This will include all prescription drugs, herbal products, vitamins, minerals, and 
over-the-counter medications . Any changes in concom itant medications will also be recorded 
in the patient ’s eCRF.  
Any concomitant medication deemed necessary for the welfare of the patient during the 
study may be given at the discretion of the Investigator . However, it is the responsibility of 
the Investig ator to ensure that details regarding the medication are recorded in full in the 
eCRF.  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537994] sign an 
informed consent form (ICF) . Patient s will have the opportunity to have any questions 
answered before signing the ICF . The Investigator must address all questions raised by [CONTACT_4677] . The Investigator  will also sign the ICF  and a signed copy will be provided to the 
patient . 
The schedule of events for the study is presented in Table  6-1. Detailed instructions for the 
conduct of study assessments and procedures will be provided in the study refere nce manual . 
 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Confidential   ITI-007 
Protocol : ITI-007-402  04 September 2019  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Confidential   ITI-007 
Protocol : ITI-007-402  04 September 2019  
 Page 62 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.  Confidential   ITI-007 
Protocol : ITI-007-402  04 September 2019  
 Page 63 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 64 
 Screening Assessments  and Procedures  
After obtaining written informed consent, the following assessments are to be performed 
within 2 weeks prior to Day 1 (unless the Medical Monitor has approved an extended screening period to allow washout of prior long-acting psychotropic medication) , acco rding 
to the schedule of events in Table  6-1; assessments can be conducted on different days within 
the S creening Period. 
6.1.[ADDRESS_537995] ( IRB)/Independent Ethics Committee (IEC) . The 
format and content of the ICF must have been agreed upon by [CONTACT_737], the appropriate IRB/IEC , and t he Sponsor. 
A separate ICF will be provided for the collection of samples to be used in the determination 
of genetic biomarkers . Patients may withhold consent to provide such samples and still 
participate in the study without prejudice.  
6.1.2 Medical History and  Other Information 
Medical history information will be collected at screening and should include (but not be limited to) demographic information, current and past medical conditions, and current and 
past medications.  The medical history must be documented in the patient’s study chart prior 
to study treatment administration and also recorded in the appropriate eCRF. In addition to conventional medical history, information pertaining to the patient ’s average alcohol  and 
caffeine consumption and average tobacco usage should be recorded in the eCRF. Demographic information will also be collected.  
Patients will be checked for previous participation in an ITI- 007 clinical study and for 
duplicate enrollment by  [CONTACT_425835].org website and other methods 
for identifying duplicate patients.  Note: Use of DupCheck applies to US patient s only. 
6.1.3 Modified Physical Examination  
A modified physical examination, including neurological and excluding genital/ rectal 
exam ination s, will be performed. The examination should include evaluation of : appearance 
and skin; head and neck; eyes, ears, nose, and throat; chest and lungs; heart; abdomen; and 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_537996] be documented in the patient’ s study 
chart and also recorded in the eCRF.  
6.1.[ADDRESS_537997] 
circumference will be measured at all scheduled visits through Visit 9 (Day 56). It is 
recommended that vital signs, waist circumfere nce, and weight are always measured after 
conducting the ECGs, as applicable, and prior to any other assessments, including needle sticks for laboratory or PK samples  scheduled for the same visit. Each patient ’s BM I will be 
calculated before Day  1 to ensure that the patient meets the BMI inclusion criterion.  
Vitals sign  measurements should also be collected, if feas ible, at the time of an AE such as 
vertigo, dizziness, fall, or any sign or symptom that might indicate a fall in blood pressure. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 66 6.1.6 Hepatitis Screening  
Blood samples will be collected at screening from all patients in order to perform hepatitis  B 
surface ant igen and hepatitis C antibody (immunoglobulin G) testing. Test results will be sent 
to the screening site and must be reviewed before the Day [ADDRESS_537998] be reviewed before  the Day 1 visit. Any 
patient who tests positive for HIV will be excluded from participating in the study. Patients 
will be informed of positive HIV results and referred for follow-up testing and counseling, and health authorities will be notified of positive HIV results consistent with federal, state , 
and local laws. D etails regarding sample collection, processing , and shippi[INVESTIGATOR_425800] . 
6.1.8 Urine Drug and Alcohol Screening  
Urine drug ( amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabi noids [THC] , cocaine 
metabolites , methadone, opi[INVESTIGATOR_858], phencyclidine, propoxyphene) and alcohol tests will be 
performed.  Any patient who tests positive for any drug, excluding prescription 
benzodiazepi[INVESTIGATOR_1651], prescription opi[INVESTIGATOR_858], and cannabinoids, or alcohol at screening w ill be 
excluded from participating in the study. Further information regarding sample collection, processing , and shippi[INVESTIGATOR_425801] . 
6.1.9 Laboratory Assessments  
Laboratory assessments performed at screening are described in Section [IP_ADDRESS]. 
6.1.[ADDRESS_537999] s 
Female patients who are of childbearing potential will undergo  serum  and urine pregnancy 
tests at the study clinic  at Screening, at the Baseline Visit (Day 1), and, at the discretion of 
the Investigator, at an Unscheduled Visit. Serum pregnancy testing will be performed using blood collected as part of protocol- specified sample; urine pregnancy testing will use a urine 
dipstick. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538000], a semi -structured interview for making 
the major DSM -5 Axis I diagnosis ( First, 2014) to be used by [CONTACT_425836], or by [CONTACT_154919]  7.0.2 ([ADDRESS_538001]  2016 version) by [INVESTIGATOR_124]. David V . Sheehan ( Sheehan et al, 1998), to be 
used by [CONTACT_105]- US sites . These assessments  will be used in this study at screening only to 
confirm the diagnosis of bipolar depression in  patients evaluated for inclusion in the study. 
The diagnostic assessment will be completed by [CONTACT_29517] a n expert site -based rater  
approved by [CONTACT_1034]. 
6.1.12  Bipolarity Index  
The Bipolarity Index (BPI)  was designed to provide a measure of quantitative measure of 
diagnostic confidence by [CONTACT_95559][INVESTIGATOR_425802] 5 dimensions of illness (signs and symptoms, age of onset, course of illness, response to treatment and fami ly history) onto a scoring hierarchy based on the presence of elements 
considered most characteristics of bipolar disorder. The information necessary to score the 
BPI [INVESTIGATOR_425803], either administered by [CONTACT_425837] a self -
report questionnaire. The BPI [INVESTIGATOR_425804]  a qualified site -based rater  at the 
screening visit. The  patient ’s responses to the BPI [INVESTIGATOR_425805] a component of the systematic patient  
adjudication process. 
The BPI  [INVESTIGATOR_425806] a group of bipolar disorder experts including Gary Sachs ( Sachs, 
2004). The scoring system is divided into 5 dimensions including epi[INVESTIGATOR_379254], age of onset ( first affective epi[INVESTIGATOR_1865]), course of illness/associated features, response to treatment, 
and family history. Each dimension is given a score of 0 to  20 based on its correlation with 
bipolar disorder characteristics, and the scores are added to derive the BPI  [INVESTIGATOR_32005]. The 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538002]. 
6.1.14  Columbia Suicide Severity Rating Scale  
The C -SSRS is a questionnaire developed and validated by [CONTACT_425838] 
(2011) for the assessment of suicidal ideation and behavior. Several versions have been 
developed including the “ Baseline” and “ Screening” versions and a combined 
“Baseline/Screening” version of the scale which assesses suicidal ideation and behavior in a 
patient ’s lifetime and during a  predefined time period. This version can assess a patient ’s 
lifetime suicidality as well as  eligibility based on inclusion/exclusion criteria. A separate 
“Since Last Visit” version of the scale has been developed which is used to assess suicidality 
since the patient ’s last visit.  This version is meant to assess patients who have completed at 
least 1 initial C -SSRS assessment  and should be used in every subsequent visit. The “ Since 
Last Visit” version of the C- SSRS addresses any suicidal thoughts or behaviors the 
patient/participan t may have had since the last  time the C -SSRS was administered.  
The C -SSRS will be administered by [CONTACT_425839] -based rater , as 
indicated in the s chedule of events ( Table  6-1).  
At screening , a potential study participant will not be eligible if he or she report s suicidal 
ideation of Type [ADDRESS_538003] 2 years prior to screening, as indicated by [CONTACT_31617] “yes” answers on the 
suicidal behavior section of the C- SSRS.  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 69 6.1.15  Young Mania Rating Scale  
The YMRS is an 11 -item, clinician -administered mania rating scale  with established 
reliability, validity,  and sensitivity that was designed to assess the severity of manic 
symptoms ( Young, 1978). Four of the YMRS items are rated on a 0 to 8 scale, with the 
remaining 7  items rated on a 0  to 4 scale. The total score is appropriate both for assessing 
baseline severity of manic symptoms and for assessing treatment -emergent manic symptoms  
in patients with Bipolar I or Bipolar II Disorder  with depression. It will be completed by [CONTACT_71339] a n expert site -based rater . 
Note: Computer- based assessments will be utilized at sites that initiated under Version 1.3 of 
this protocol or prior versions. Assessments completed at sites initiated with  Version 1.4 and 
any future versions of the protocol will be paper- based.  
At each visit  with a YMRS assessment , the rater -administered YMRS interviews will be 
audio recorded  (this applies to computer- administered assessment only ); at each visit after  
the screening  visit, a computer- administered  interview will also be completed by [CONTACT_1962] . 
Where computer -administered assessments are not being used, the assessment completed by 
[CONTACT_425840] -based . 
6.1.16  Clinical Global Impression  Scale  of Bipolar Illness –Severity  of 
Illness  
The Clinical Global Impres sions Scale has been modified specifically for use in assessing 
global illness severity and change in patients with bipolar disorder (CGI -BP-S) (Spearing, 
1997). The CGI -BP-S is a standardized assessment tool that  a clinician can use to rate the 
severity of illness, change over time, and efficacy of medication,  taking into account the 
patient ’s clinical condition and the severity of side effects. The CGI -BP-S is used to 
document the clinician ’s impression of the patient’ s current illness  state; it will be used in 
this study at screening (as a criterion for inclusion or exclusion) and throughout the study as a 
measure of efficacy  (Section 6.2.2). Scores on the CGI-BP-S range from 1 (not ill at all) to 7 
(among the most extremely ill). A CGI -BP-S assessment will be  completed by [CONTACT_425841]-approved expert site -based rater . The D epression  score is 
based on the clinician ’s assessment of depression  symptom severity; the Mania score is based 
on the clinician ’s assessment of mania symptom severity; and the Overall score is based on 
the clinician ’s overall impression  of illness severity.   
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538004] designed to measure the overall severity of depressive 
symptoms . Individual items are rated by [CONTACT_737]  (or another Sponsor-approved 
expert site -based rater) on a scale of [ADDRESS_538005] severe 
symptoms for each item assessed . The total score ranges from 0 to 60. The MADRS is 
administered using a structured interview to ensure reliability and c ompleteness. T he format 
of the interview varies by [CONTACT_425842] ( SIGMA ; when paper forms are used) or a similar interview structure when 
electronic tablets are used for scoring.  
Note: Computer- based assessments will be utilized at sites that initiated under Version 1.3 of 
this protocol or prior versions. Assessments completed at sites initiated with Version 1.4 and any future versions of the protocol will be paper- based.  
Remission of depression based on the MADRS is generally defined as a patient  with a 
MADRS total score of ≤ 12 at endpoint. A response based  on the MADRS is defined as a 
≥50% reduction from baseline in total MADRS score at endpoint. 
The total score on the MADRS at screenin g is a major criterion for inclusion in the study, as 
well as the primary outcome measure for the study . 
At each visit  with a  MADRS assessment, the rater -administered MADRS interview will be 
audio recorded  (note: audio-recording applies to computer- based assessments only) . At each 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538006] data for scoring MADRS . 
6.2.2 Clinical Global Impression  of Bipolar Illness –Severity  
The CGI -BP-S, described in Section 6.1.16, will be a clinical efficacy assessment by [CONTACT_425843] ’s severity of illness. The C linical Global Impression Scale  is a 
widely accepted measure of illness severity in a va riety of psychiatric disorders. The CGI -
BP-S will be assessed  at Baseline/Visit 2, Visits 3 -8, and Visit 9/ET. Details related to  the 
statistical analysis of  the CGI -BP-S scores  are provided in Section s 7.5.5 and 7.5.6. 
6.2.3 Sheehan Disability Scale  
The SDS is a validated patient self -reported  measure of psychosocial disability. It is widely 
used in many chronic mental illnesses because of its generic design. The SDS consists of 
3 subscales for the items "Work/School," "Social Life," and "Family Life/Home Responsibilities."  Each subscale consists of a visual analog scale on which the patient scores 
each item  from 0 ("not at all") to 10 ("extremely") in response to each question of how much 
each subscale aspect is impaired.  Changes in the score for each item are evaluated to assess 
the change in severity of each domain. The scores may also be summed across the 3 subscales to assess overall change in disability.  Note: This scale is to be administered to US 
patient s only. 
6.2.4 Quality of Life Enjoyment and Satisfaction Questionnaire – Short 
Form 
The Q -LES-Q- SF is a patient self -report ed questionnaire that assesses how satisfied a patient 
is, using a 5-point rating scale from very poor to very good, with [ADDRESS_538007]/interest/performance, economic status, living/housing situation, ability to get around 
physically without feeling dizzy or unsteady or falling, vision in terms of ability to do work 
or hobbies, and overall sense of well -being that are summed to provide a raw total score 
ranging from 14 to 70. here are an additional 2 stand -alone items ( 1 for medication 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 72 satisfaction and the other for overall life satisfactio n). The total raw score is converted to a 
percent score.  
6.2.[ADDRESS_538008], each rated on a 6-point 
Likert scale from 0 (at no time) to 5 (all the time).  The sum of scores represents the raw 
scores with [ADDRESS_538009] 
possible quality of life. A score below 13 represents poor well- being.  To calculate the 
percentage score, the raw score is multiplied by 4, with 100% representing the best possible quality of life.  A 10% difference over time indicates a meaningful change.  The WHO -[ADDRESS_538010] adequate validity as an outcome measure in clinical studies ( Topp, 2015).  
Note:  This scale is to be administered to US patients only.  
6.2.6 Neuroticism, Extraversion, and Openness to Experience -Five Factor 
Inventory 
The NEO -FFI is a 60 -item self -report scale ( Costa, 1992). Each item is ranted on a 5-point 
scale.  Twelve items assess each of 5 dimensions of personality: neuroticism (N), extraversion 
(E), conscientiousness (C), openness (O), and agreeableness (A). Note:  This scale is to be 
administered to US patients only. 
 Patient Placebo -Response Training  
A brief  training explaining the use of placebo in this study will be provided to all patients at 
Baseline (Visit 2). In addition, site staff will receive a brief training defining the placebo response in clinical drug trials. Completion of placebo-response training will be documented 
for both patient and site staff.  
 Safety and Tolerability Assessments  
All patients who receive study medication  will be evaluated for safety.  Safety assessments 
will include incidence of AEs; suicidality assessment by [CONTACT_941] C- SSRS; mania assessment by 
[CONTACT_211408] ; movement disorder assessment by [CONTACT_425844], BARS and SAS ; clinical laboratory 
evaluations; ECG evaluations; vital sign measurements ; and physical and neurological 
examinations . 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 73 6.4.1 Adverse Events  
The Investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study medication  or their clinical significance.  
[IP_ADDRESS]  Definition  of Adverse Event  
An AE is any untoward medical occurrence in a study patie nt administered a study 
medication , whether or not considered drug related. This can be any unfavorable and 
unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a study medication , without any judgment of causality.  
The AE may be:  
• A new illness;  
• A worsening sign or symptom of the condition under treatment, or of a concomitant 
illness;  
• An effect of the study medication , including comparator; or 
• A combination of 2 or more of these factors. 
No caus al relationship with the study medication  or with the clinical study itself is implied by 
[CONTACT_425845].  
Surgical procedures themselves are not AEs; they are therapeutic measures for conditions 
that require surgery.  The condition for which the surgery is required may be an AE.  Planned 
surgical measures, if permitted by [CONTACT_425846].  
All AEs fall into the categories of “nonserious ” or “serious” (Sections [IP_ADDRESS] and [IP_ADDRESS]). 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments ( eg, ECGs, vital sign measurements), including those that worsen from 
baseline, felt to be clinically significant, in the medical and scientific judgment of the investigator, are to be recorded as AEs or SAEs. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 74 However, any clinically significant safety assessments that are associated with the underlying 
disease, unless judged by [CONTACT_166538]’ s 
condition, are not to be reported as AEs or SAEs.  
[IP_ADDRESS]  Definition of Serious Adverse Event  
An SAE is defined as any untoward medical occurrence that at any dose:  
• Results in death; 
• Is life threatening;  
• Requires hospi[INVESTIGATOR_211384]; 
• Results in persistent or significant disability or incapacity; or  
• Is a congenital anomaly or birth defect.  
The term “ life threatening ” refers to an event in which the patient  is at risk of death at the 
time of the event; it does not refer to an event, which hypothetically might have caused death if it were more severe.  
Medical and scientific judgment should be exercised in deciding whether an AE is serious. 
Some important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_425807] [ADDRESS_538011] be 
considered and evaluated by [CONTACT_425847]. 
Clarification of the difference between "serious" and "severe":  
The term “ severe” is often used to describe the intensity (severity) of a specific event (as in 
mild, moderate, or severe myocardial infarction); the event itself, however, may be of 
relatively minor medical significance (such as a severe headache).  This i s not the same as 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 75 “serious,” which is based on patient/event outcome or action criteria usually associated with 
events that pose a threat to a patient ’s life or functioning. Seriousness (not severity) serves as 
a guide for defining regulatory reporting obl igations.  
[IP_ADDRESS]  Nonserious Adverse Event  
A nonserious AE is any AE not meeting the SAE criteria.  
[IP_ADDRESS]  Definition of Relationship to Study Medication  
By [CONTACT_108], any AE that starts before the first dose of study medication  administration is 
considered to be “unrel ated.” 
The Investigator will assess the causality/relationship between the study medication  and the 
AE (Table  6-2). One of the following categories should be selected based on medical 
judgment, considering the following definitions and all contributing factors. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538012] abnormality, occurs in a 
plausible time relationship to treatment administration, and which 
concurrent disease or other drugs or chemicals cannot explain. The response to withdrawal of the treatment (dech allenge
1) should be 
clinically plausible.  The event must be definitive pharmacologically or 
phenomenologically, using a satisfactory rechallenge2 procedure if 
necessary.  
Probably related  A clinical event, including laboratory test abnormality, with a reas onable 
time sequence to administration of the treatment, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which 
follows a clinically reasonable response on withdrawal (dechallenge).  
Rechallenge information is not required to  fulfill this definition.  
Possibly related  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the treatment, but which could also be explained by [CONTACT_9153].  
Information on- treatment withdrawal may be lacking or unclear.  
Unlikely to be 
related  A clinical event, including laboratory test abnormality, with a temporal 
relationship to treatment administration which makes a causal relationship improbable, and in which other drugs, chemicals or 
underlying disease provide plausible explanations. 
Unrelated  A clinical event, including laboratory test abnormality, with little or no 
temporal relationship with treatment administration.  May have negative 
dechallenge and rech allenge information.  Typi[INVESTIGATOR_897], explained by 
[CONTACT_211417] ( eg, concomitant disease, environmental factors, or 
other drugs or chemicals).  
1 Dechallenge is when a drug suspected of causing an adverse event (AE) is discontinued.  If the symptoms of 
the AE disappear partially or completely, within a reasonable time from drug discontinuation, this is termed a 
positive dechallenge.  If the symptoms continue despi[INVESTIGATOR_211386], this is termed a negative 
dechallenge. Note that there are exceptions when an AE does not disappear upon discontinuation of the drug, 
yet drug -relatedness clearly exists (eg,  bone marrow suppression, fixed drug erup tions, tardive dyskinesia).  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538013] is readministered to 
that patient.  If the AE recurs upon exposure, this is termed a positive rechallenge.  If the AE does not recur, this 
is termed a negative rechallenge.  
[IP_ADDRESS]  Definition of Intensity 
The Investigator will assess all AEs for intensity ( severity ) in accordance with  the following 
standard ratings  (Table  6-3): 
Table  6-3 Intensity Categories  
Category  Definition  
Mild  Ordinarily transient symptoms ; does not influence performance of 
patient ’s daily activities.  Treatment is not ordinarily indicated.  
Moderate  Marked symptoms, sufficient to make the patient  uncomfortable.  
Moderate influence on performance of patient ’s daily activities. 
Treatment may be necessary.  
Severe  Symptoms cause considerable discomfort. Substantial influence on 
patient ’s daily activities.  May be unable to continue in the study and 
treatment may be necessary.  
Life threatening  Extreme limitation in activity, signif icant assistance required; 
significant medical intervention/therapy required, hospi[INVESTIGATOR_244502].  
 
When changes in the intensity of an AE occur more frequently than once a day, the maximum 
intensity for the event should be noted for that day. Any change in intensity of signs and 
symptoms over a number of days will be captured by [CONTACT_44745] a new AE, with the amended 
intensity grade and the date (and time, if known) of the change.  
[IP_ADDRESS]  Period of Observation for Adverse Events 
For the purposes of this study, the period of observation extends from the time the patient 
gives his study-specific informed consent until the end-of-study procedures are completed. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538014] the 
Sponsor to determine how the AE should be documented and reported. 
[IP_ADDRESS]  Documenting , Reporting , and Eliciting Adverse Events   
All AEs reported or observed during the study will be collected and recorded on the AE page 
of the eCRF  for each patient from the date the ICF was signed until the end of their 
participation in the study , ie, the patient has discontinued or completed the study. 
Adverse events may be volunteered spontaneously by [CONTACT_102], or discovered by [CONTACT_310175], non-leading question such as, “ How 
have you been feeling since you were last asked? ” All AEs and any required remedial action 
will be recorded.  The nature of the AE, date (and time, if known) of the AE onset, date (and 
time, if known) of the AE outcome to date, severity, and action taken for the AE will be 
documented together with the Investigator’s assessment of the seriousness of the AE and causal relationship to study medication  and/or study procedure. 
All AEs should be recorded individually in the study patient’s own words (verbatim) unless, in the opi[INVESTIGATOR_689] , the AEs constitute components of a recognized condition, 
disease or syndrome. In the latter case, the condition, disease or syndrome should be named rather than each individual symptom. The AEs will subsequently be coded using the latest version of Medical Dictionary for Regulatory Activities (MedDRA). 
[IP_ADDRESS]  Notification About Serious or Unexpected Adverse Events  
The Investigator will review each SAE (Section [IP_ADDRESS]) and evaluate the intensity and the 
causal relationship of the event to study medication . All SAEs will be recorded from signing 
of informed consent until follow-up. 
The Investigator is responsible for providing notification to the Sponsor or designee of any 
SAE, whether deemed related to study medication  or not, that a patient  experiences during 
their participation in study within 24 hours of becoming aware of the event. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 79 As a minimum requirement, the initial notification should provide the following information: 
• Study number; 
• Patient  number; 
• Gender ; 
• Date of birth ; 
• Name [CONTACT_425864] ; 
• Details of SAE ; 
• Criterion for classification as “serious”; 
• Study medication  code, or name [CONTACT_211439], and treatment start date and stop date, 
if applicable ; 
• Date of SAE onset ; 
• Causality assessment (if sufficient information is available to make this 
classification) . 
The Sponsor will request clarification of omitted or discrepant information from the initial 
notification. The Investigator or an authorized delegate is responsible for faxing the requested 
information to the Sponsor within 24 hours of the Sponsor’ s request.  
Initial reports of SAEs must be followed later with detailed descriptions, including clear photocopi[INVESTIGATOR_211387] ( eg, hospi[INVESTIGATOR_73529], consultant reports, autopsy 
reports), with the study patient ’s personal identifiers removed. All relevant information 
obtained by [CONTACT_425848] [ADDRESS_538015]. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538016] information will be provided to all participating study sites by [CONTACT_425849].  
[IP_ADDRESS]  Exceptions 
Visits to urgent care or emergency room facilities may not warrant reporting as SAE s unless 
the patient is admitted to the hospi[INVESTIGATOR_425808] “serious” criteria.  As discussed 
in Section [IP_ADDRESS], m edical and scientific judgment should be exercised in deciding whether 
an AE is serious. Events that are not clearly meeting “serious” criteria can be discussed on a 
case- by-case basis with the Medical Monitor to help the Investigator determine whether the 
event meets “serious” criteria.  
[IP_ADDRESS]  Follow -Up of Adverse Events 
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution , until the Investigator deems the event to be chronic or not clinically 
significant, or until the patient  is considered to be stable.  
A follow-up telephone call will be performed for those patient s with an ongoing AE which 
the Investigator believes to be not related to study medication  administration.  A follow-up 
visit to the study site may occur for those patient s with an ongoing AE which the Investigator 
believes to be possibly related to study medication  administration.  
All AEs must be reported in detail on the appropriate page in the eCRF and followed until they are  resolved or stable, or judged by [CONTACT_425850].  
6.4.2 Other Safety Assessment s 
[IP_ADDRESS]  C-SSRS  
The C -SSRS will be completed  at screening, baseline, and at every subsequent scheduled 
clinic visit ( Table  6-1).  Details of the C -SSRS are presented in Section 6.1.13. 
[IP_ADDRESS]  YMRS  
The YMRS will be completed  at screening, baseline, and at every subsequent scheduled 
clinic visit ( Table  6-1).  Details of the YMRS are presented in Section 6.1.15. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 81 [IP_ADDRESS]  Abnormal Involuntary Movement Scale  
The AIMS (Guy, 1976) measures facial and oral movements, extremity movements, and 
trunk movements. Seven items are rated on a scale from none (0) to severe (4).  A score of 
“mild” (2) in 2 or more categories or a score of “ moderate” or “ severe” in any 1 category 
results in a positive AIMS score ( ie, the scores are not averaged).  Additionally, overall 
severity is scored on the basis of severity of abnormal movements and incapacitation due to 
abnormal movements. The patient ’s awareness of and distress caused by [CONTACT_425851]. The AIM S is to be completed at baseline and periodically 
throughout the study as specified in the schedule of events ( Table  6-1). 
[IP_ADDRESS]  Barnes Akathisia Rating Scale  
The BARS is a rating scale for drug -induced akathisia developed by [CONTACT_143490] ( 1989).  It 
includes the rating of observable restless movements, the subjective awareness of 
restlessness, and the distress associated with the akathisia.  There is also a global rating for 
severity.  The scale is completed by [CONTACT_29517] a n expert site -based rater  after a 
standard examination. Objective akathisia, subjective awareness and subjective distress are 
rated on a 4 -point scale from 0 to 3, yielding a total score from 0 to 9. the global clinical 
assessment of akathisia is rated separately, on  a 5-point scale from 0 to 4. T he BARS  is to be 
completed at baselin e and periodically throughout the study as specified in the schedule of 
events ( Table  6-1). 
[IP_ADDRESS]  Simpson  Angus Scale  
The SAS  is a measure of extrapyramidal side effects ( Simpson, 1970).  Ten items including 
rating gait, arm droppi[INVESTIGATOR_007], shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, glabella tap, tremor, and salivation are rated on a scale from 0 (normal) to 4 
(extreme in severity).  The SAS  should be conducted by [CONTACT_29517] a n expert 
site-based rater  in a room where the patient can  walk a sufficient distance to allow a natural 
pace ( eg, 15 paces). Each side of the body should be examined. The SAS  is to be completed  
at baseline and periodically through out the study as specified in the schedule of events 
(Table  6-1). 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 82 [IP_ADDRESS]  Vital Sign Measurements 
Vital signs will be measured at screening and at every subsequent scheduled clinic visit 
(Table  6-1). Details of the vital sign measurements are presented in Section 6.1.5. 
[IP_ADDRESS]  ECG Assessments 
The ECG assessments will be performed at screening and periodically throughout the study, 
as scheduled ( Table  6-1). Details of the ECG assessments are presented in Section 6.1.4. 
[IP_ADDRESS]  Physical and Neurological Examinat ion 
The physical and neurological examinations will be conducted at screening and periodically 
throughout the study, as scheduled ( Table  6-1). Details of the physical and neurological 
examinations are presented in Section 6.1.3. 
[IP_ADDRESS]  Laboratory Analyses 
Blood and urine samples collected from patients will be forwarded to a central l aboratory for 
analysis.  The Investigator must review all laboratory results for all patients. If a lab oratory 
value is reported as deleted, cancelled, unable to perform, or otherwise missing, the test must 
be repeated as soon as possible.  If the Investigator determines that the missing value does not 
require an immediate repeat, he/she must provide clinical reasoning to the Sponsor or its 
representative.  
Additional details regarding sample collections, processing and specific testing can be found 
in the study reference manual . 
All samples for clinical laboratory analysis will be collected after an overnight fast (≥10 hours), after any scheduled ECG or vital signs have been recorded, and prior to dosing 
with study medication . Samples for clinical la boratory analysis will be used only for the 
evaluation of safety and tolerability. 
The following clinical analytes will be determined:  
Hematology:  hematocrit ; hemoglobin; HbA
1c; red blood cell count with indices (mean 
corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin 
concentration); reticulocytes ; white blood cell count and differential (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils) reported as percent (%) and absolute 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 83 values ; and platelets (platelet count,  prothrombin time and partial thromboplastin  time , 
international normalization ratio ). 
Clinical chemistry:  albumin ; alkaline phosphatase; blood urea nitrogen; gamma -glutamyl 
transferase; calcium ; creatinine ; glucose; insulin ; cholesterol  (high-density lipoprotein and 
low-density lipoprotein [ LDL] [ calculated ] and homogenous LDL will be reported, and 
homogenous LDL will be reflexed if a patient ’s triglycerides are >400); triglycerides ; 
phosphate; potassium; prolactin ; ALT; AST ; lactate dehydrogenase; sodium; chloride; 
bilirubin (total, direct) ; total protein ; uric acid ; creatine phosphokinase . Thyroid panel 
(thyroid -stimulating hormone ) will be  assayed  at Screening (Visit 1) and at Visit 8 (end of 
Treatment Period) or at Visit 9 (Early D iscontinuation) . If the result is abnormal, the free 
thyroxine and free triiodothyronine will be assayed. 
Urinalysis:  macroscopic (pH, specific gravity, glucose, protein, ketones, nitrates, blood) and 
microscopic – report only if present (red blood cell s/high-power field , white blood cell s/high-
power field , casts, epi[INVESTIGATOR_1663], crystals, granulation).  
Serology:  anti-HIV antibodies, hepatitis B surface antigen , and hepatitis C antibody (only 
during screening). 
Drug Assays:  Lithium and valproate blood levels will be assessed  at screening and at each 
specified visit to assess maintenance within  the respective therapeutic ranges.  
 Safety Monitoring Committee 
No safety monitoring committee will be used for the study.  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 84 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538017] be followed up to determine outcome 
(including spontaneous miscarriage, elective termination, normal birth, or congenital 
abnormality) and status of mother and child, even if the patient was discontinued from the 
study.  Pregnancy complications and elective terminations for medical reasons should not be 
reported as an AE or SAE. Spontaneous miscarriages must be report ed as an SAE.  
Completion of the pregnancy form is not required for screen-failed patients who have had 
positive pregnancy test(s). 
Any SAE occurring in association with a pregnancy brought to the Investigator’ s attention 
after the patient has completed the study, and considered by [CONTACT_425852], must be promptly reported to the Sponsor. 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 86 7 Statistical and Analytical Plan  
A formal and detailed statistical analysis plan  (SAP) will be finalized prior to the planned 
interim analysis and  will provide further details regarding the definition of analysis 
endpoints, analysis methodology, and the interim analysis to address all study objectives.  
Changes made to the data analysi s methods as described in this protocol will be documented 
in the SAP and will not necessitate a protocol amendment. All departures from the statistical 
analyses described in the approved protocol, whether made before or after unblinding, will be 
documented, and justified in the final clinical study report. 
A blinded data review will be conducted prior to unblinding the patient s’ treatment 
assignment s for assessing  the accuracy and completeness of the study database and defining 
analysis sets .  
 Analysis End points  
7.1.1 Primary Efficacy Endpoints  
The primary efficacy endpoint is the change from baseline to Day 43 in the 
rater-administered MADRS total score.   
7.1.2 Key Secondary Efficacy Endpoint  
The key secondary efficacy endpoint is the mean change from baseline to Day 43 in the CGI-BP-S-Depression score. 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 87 7.1.4 Safety  Endpoints  
• AEs;  
• YMRS total score;  
• C-SSRS scores;  
• AIMS scores;  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 88 • BARS scores;  
• SAS score;  
• Physical examination and neurological findings; 
• Vital signs (blood pressure, heart rate), weight, and waist circumference;  
• ECGs;  
• Clinical laboratory evaluations.  
 Sample Size Calculations  
The sample size calculation of the study is based on the primary efficacy endpoint , the 
change from baseline to Day 43 in MADRS total score. Adjusting for multip le comparisons 
of two ITI-007 treatment groups with placebo by [CONTACT_425853] (test the 
[ADDRESS_538018] the 40 mg placebo vs placebo), a sample size of approximately 520 patients (173 per group) will provide 
approximately 90% power to detect an effect size of 0.4. Th is sample size estimation also 
assume s a common  dropout rate of 15% a t Day 43, and a common w ithin-patient correlation 
of 0.7 for the change from baseline in MADRS  total scores at Days 8, 15, 22, 29, 36, and 43. 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 89 
 Analysis Sets 
The following analysis sets will be used in the statistical analyses : 
All Enrolled (ENR) Set: The ENR Set will contain all patients who signed the informed 
consent for the study; 
All Patients Randomized (RND) Set: The RND Set will contain all patients who signed the 
informed consent and were randomized to study medication. Patients will be classified 
according to randomized treatment ; 
Intent- to-treat (ITT) Set : The ITT Set will contain  all random ly assigned  patients who 
received at least 1 dose of study medication  and who had a valid baseline (pre-dose) 
measurement and at least [ADDRESS_538019]- baseline measurement of MADRS . All analyses using 
the ITT Set will classify patients accor ding to randomized treatment, regardless of the 
treatment actually received during the course of the study; 
Sensitivity Set: The Sensitivity Set will contain all randomly assigned patients who received 
at least 1  dose of study medication and who had a valid baseline (pre- dose) measurement 
MADRS total score.  All analyses using the Sensitivity Set will classify patients accordin g to 
randomized treatment, regardless of the treatment actually received during the course of the 
study.  
Safety Set : The Safety Set will contain  all patients who received at least 1 dose of study 
medication . All analyses using the Safety Set will classify patients according to treatment 
actually received ; 
PK Set : The PK Set will contain  all patient s who received study medication , a baseline as 
well as at least [ADDRESS_538020] 1 PK sample 
collected and analyzed.  Proto col deviations ( eg, dosing errors) and AEs (eg, emesis) will be 
considered when assigning patient s to the PK Set ; patients who experience such events may 
be excluded from the PK Set on a case -by-case basis.  
Unless otherwise specified, the ITT Set will be used for analysis of efficacy endpoints and 
the Safety Set will be used for analysis of safety endpoints. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 90 
 Description of Subgroups to be Analyzed 
In addition to the ITT Set, efficacy measures will be analyzed by a subgroup defined by [CONTACT_425854]  (lithium or valproate). Other s ubgroup analyses of efficacy and safety 
variables may be conducted as deemed appropriate  and will be detailed in the SAP.  
 Statistical Analysis Methodology 
Categorical variables ( eg, AEs) will be summarized using  the numbe r and percentage of 
patients in specified categories.  Unless otherwise specified, the calculation of percentages 
will be based on the number of patients in the analysis set of interest. Continuous variables 
(eg, MADRS scores ) will be summarized using descr iptive statistics, including  number of 
patients, mean, standard deviation, median, minimum, and maximum. 
First treatment with study medication and baseline assessments are scheduled for Visit [ADDRESS_538021] treatment.  Assessments on Day 1 for which the time is missing, and are, according to the 
study schedule of events, supposed to be collected prior to treatment, will be considered 
baseline.  
Safety, efficacy, and quality of life data will be listed for all treated patients and summarized 
by [CONTACT_6982], unless stated otherwise in the SAP. All total and subscale s cores 
will be derived from available individual items.  In case of missing items, the total and 
subscale scores will be considered missing. Plasma concentrations below the limit of quantification will be flagged in the data listings and will be set to 0 in the calculation of summary statistics of concentration values and derivations of PK parameters. 
Unless stated otherwise, statistical tests will be 2 -sided significant level of 0.05, leading to 
95% (2 -sided) confidence intervals (CIs). 
All investigative sites with fewer than 6 ITI-007 patients will be pooled as follows: t he 
largest site with fewer than  [ADDRESS_538022] investigative site within the same 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 91 country or geographic region, if one exists; otherwise, no further pool ing is needed . If the 
primary efficacy analysis model presents convergence issues due to the too small number of 
patients per site, including pooled sites, the same site pooling algorithm will be applied again, but this time pooling sites with fewer than a pre -specified larger number of ITI-[ADDRESS_538023].  The actual investigative site 
numbers will be included in the listings.  
Additional details regarding the statistical analysis methodology will be provided in the SAP.  
All statistical analysis will be performed using SAS® softw are Version 9.4 or higher. 
7.5.1 Patient Disposition, Analysis of Demographics and Other Baseline 
Characteristics  
Patient disposition will be summarized by [CONTACT_1570] , when applicable, and overall, and 
by [CONTACT_425816], including incidence of screening failure and incidence of treatment  or study discontinuation and the corresponding reasons. The number and 
percentage of randomized patients  who discontinued due to an AE associated with worsening 
of bipolar depression will be summarized. Similarly, the number and percentage of randomized patient s who discontinued due to an AE not associated with worsening of bipolar 
depression will also be presented. Time to treatment discontinuation due to all reasons, AEs 
(all, AEs associated with worsen ing of bipolar depression, and AEs not associated with 
worsening of bipolar depression) , lack of efficacy, or due to any other reason of special 
interest will be evaluated separately using the Kaplan -Meier method.  The Log -rank test will 
be used to compare the time to discontinuation between each treatment group and the placebo group. 
Demographic and baseline characteristics , including bipolar disorder diagnosis and baseline 
efficacy measures,  will be listed and summarized by [CONTACT_6654] . No 
inferential statistics will be presented.  
7.5.[ADDRESS_538024]-treatment medications, defined by [CONTACT_425855], will be summarized by [CONTACT_425856] -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538025] treatment with ITI-007. 
7.5.3 Study Medication Exposure and Treatment Compliance  
Exposure to study medication and treatment compliance will be presented for the ITT and 
Safety S ets. Duration of exposure (days) and dosing compliance (%) will be calculated and 
summarized by [CONTACT_1570].  In addition, the number and percentage of patients exposed 
to study medication will be presented by [CONTACT_95839] , defined by [CONTACT_211424]. 
7.5.[ADDRESS_538026]  
model repeated measures (MMRM)  method. The model will include the  change from 
baseline at each pre- specified time  point in the rater -administered MADRS total score as the 
response variable,  and visit, treatment  group, site  (or pooled site), and the stratification 
variables,  first-line treatment ( lithium or valproate ) and  Bipolar Disorder type at screening 
(I or II), and int eraction term for treatment group -by-visit interaction as fixed effects, and the 
baseline MADRS total score and baseline MADRS total score- by-visit interaction as 
covariates . The patient term will be included in the model as a  random effect and other terms  
as fixed effects.  The treatment group -by-site (or pooled site) interaction term will not be 
included in the MMRM model for the primary efficacy analysis.  Rather , it will be examined 
as part of the exploratory analysis.  An unstructured covariance matrix will be used to model 
the correlation among repeated measurements within patien t. In the event the convergence 
cannot be attained with the unstructured correlation matrix, the following alternative structures will be attempted in the specified order: heterogeneous Toeplitz structure 
(TOEPH), heterogeneous autoregressive (1) (ARH [1]), heterogeneous compound symmetry, 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 93 No Diagonal Factor Analytic (FA0(q), with q equal to the number of time points) , Toeplitz 
structure (TOEP), autoregressive (1) (AR [1]), and compound symmetry. Model parameters 
will be estimated using restricted maximum likelihood . The Kenward -Roger approximation 
will be used to estimate the denominator degrees of freedom. The treatment group and 
treatment group -by-visit interaction terms all ow for comparisons of the treatment groups at 
each of the following:  Days  8, 15, 22, 29, 36, and 43. Treatment differences will be evaluated 
via contrasts for the treatment group- by-visit factor.  This methodology will be used to 
compare each of the ITI-[ADDRESS_538027] errors and 95% CIs for LSMs will be presented by [CONTACT_425857].  Contrast estimates (LSMs) for between -group 
comparisons, the corresponding standard errors, 95% CIs, effect sizes, and p- values will be 
presented for day. 
A number of s ensitivity analyses  of the primary efficacy endpoint will be perfo rmed  to 
explore the robustness of the MMRM results under a different assumption on the mechanism 
of missing  data. All sensitivity analyses will be performed based on the Sensitivity Set.  The 
MMRM method assumes a missing -at-random mechanism for missing data. That is, the 
probability that measurements are missing depends on the set of observed measurements but is unrelated to the specific unobserved missing values that, in principle, should have been obtained.  Sensitivity analyses will be conduct ed to assess the impact of missing data under 
different assumptions on the mechanism of missing data and will be detailed in the SAP. 
Additionally, as a supportive analysis of the primary efficacy variable, the change from 
baseline to Day 43 in MADRS total  score will be evaluated using analysis of covariance 
(ANCOV A ) model with  last observation carried forward ( LOCF ) based on the ITT Set . The 
model will contain the main effects of treatment group, site (or pooled site), the baseline value of MADRS total score, and the stratification v ariables (first -line treatment - lithium or 
valproate) and the bipolar disorder at screening [ I or II ]). Analysis of the LOCF Day  [ADDRESS_538028] err ors and 
2-sided 95% CIs for the differences between the treatment groups, and p- values for between -
treatment tests of differences will be presented.  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 94 7.5.5 Analysis of  Key Secondary Efficacy Endpoint  
The key secondary efficacy endpoint of the study is the change from baseline to Day 43 in 
the CGI -BP-S-Depression score. The key secondary efficacy endpoint will be analyzed using 
the similar MMRM model as for the primary efficacy endpoint. Details will be provided in the SAP.  
A fixed sequence procedure will be employed to control the overall type I error rate for 
multiple comparisons across the primary and the key secondary efficacy endpoints for the 60-mg and 40 mg treatment groups. Specifically, the primary and the key secondary efficacy endpoints will be tested in the following specified order:  
 #1: ITI -007 60 mg vs placebo comparison for change from baseline in MADRS total 
score at Day 43 ; 
 #2: ITI -007 40 mg vs placebo comparison for change from baseline in MADRS total 
score at Day 43 ; 
 #3: ITI -007 60 mg vs placebo comparison for change from baseline in CGI- BP-S 
score at Day 43 ; 
#4: ITI -[ADDRESS_538029] statistical significance.  

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 95 7.5.7 Safety Analyses  
Safety data such as reported and observed AEs, TEAEs, SAEs, clinical laboratory results, 
vital signs, physical examinations and neurological findings, ECGs, and the different rating 
scales (Y MRS, C- SSRS, AIMS, BARS, and SAS) will be summarized by [CONTACT_103374]. When appropriate, out-of- range values will be flagged in data listings and 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538030] 5% of patients in any treatment group 
will be summarized.  Additional summaries of TEAEs will be presented as deemed necessary 
and will be specified in the SAP. 
Patients who discontinue study or study medication due to AEs will be listed and 
summarized by [CONTACT_6657].  
Treatment -emergent AEs will be categorized to monitor signals of potential abuse of ITI-[ADDRESS_538031] 1 abuse- related TEAE will be 
summarized by [CONTACT_3433] e pre- specified categories.  
Laboratory assessments, including hematology and chemistry, vital signs, and ECGs, will be 
listed and summarized by [CONTACT_6982]. Summaries may include actual and change from baseline, incidence of abnormal values according to normal range criteria, shift from baseline to each visit according to markedly abnormal criteria, and listing of patients 
meeting markedly abnormal criteria.  Certain chemistry results, including but not limited to 
blood levels of fasting glucose, total cholesterol, triglycerides, and insulin will be evaluated 
for whether there is a difference between ITI-007 and placebo, using ANCOV A with LOCF. 
Any comparison between the treatment groups will be considered exploratory. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 97 The observed values and changes from baseline in the scores of the rating scales (YMRS, 
C-SSRS, AIMS, BARS, and SAS) will be summarized by [CONTACT_67486]. 
7.5.9 Blinded Sample Size Re -estimation  
A blinded sample size re- estimation  may  be performed when 70% of randomized patients 
have either completed the study or discontinued to obtain an estimate of the pooled standard 
deviation on change from baseline to Day [ADDRESS_538032] deviation in the sample size calculation , sample sizes may be increased to ensure an adequate power. The number of 
patients in each treatment arm will be capped at 200.  
Details on the blinded sample size re- estimation will be provided in the SAP.  
 Estimand Framework  
An estimand framework will also be employed to assess the efficacy of ITI -007 and its detail 
will be presented in the SAP of this study. 
 Data Quality Assurance 
To ensure complia nce with Good Clinical Practice ( GCP ) and all applicable regulatory 
requirements, ITI  (the Sponsor) or its designee may conduct a quality assurance audit of the 
study site records and  regulatory agencies may conduct a regulatory inspection at any time 
during or after the study. In the event of an audit or inspection, the Investigator (and 
institution) must agree to grant the auditor(s) and inspector(s) direct access to all relevant 
documents and to allocate their time and the time of their staff to discuss  any 

Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 98 findings/relevant issues.  Responsibility for the accuracy, completeness, and reliability of the 
study data presented to the Sponsor lies with the Investigator  generating the data.  
7.7.[ADDRESS_538033] or MINI ( Table  6-1), lab oratory reports, and ECG strips . 
Investigative site personnel will enter patient data into electronic data capture (EDC) . All 
eCRF fields are to be filled in.  If an item is not available or is not applicable, this fact should 
be indicated.  Blank fields should not be present unless otherwise directed. The analysis data 
sets will be a combination of these data and data from other sources ( eg, laboratory data). 
Clinical data management will be performed in accordance with applicable Sponsor 
standards and data-cleaning procedures to ensure the integrity of the data, eg, removing 
errors and inconsistencies in the data. Adverse events and concomitant medication terms will 
be coded using MedDRA, and  an internal validated medication dictionary , respectively . 
After database lock, each study site  will receive  an electronic data storage device containing 
all of their  study site - specific eCRF data as entered into the EDC , including full discrepancy 
and au dit history.  Additionally, a n electronic  copy  of all of the study site ’s data will be 
created and sent to the Sponsor for storage . The CRO  will maintain a duplicate electronic 
copy for their records . In all cases, patient  initials will not be collected or transmitted to the 
Sponsor. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538034] 
Federal regulations and the International Council for Harmonisation (ICH) guidelines require 
that approval be obtained from an IRB/IEC  before participation of human patients in research 
studies. Before study onset, the protocol, informed consent, advertisements to be used for the 
recruitment of study patient s, and any other written information regarding this study to be 
provided to the patient  or the patient ’s legal guardian must be approved by [CONTACT_1201]/IEC. 
Documentation of all IRB/IEC approvals and of the IRB/IEC compliance with ICH 
harmonised tripartite guideline E6(R1) GCP will be maintained by [CONTACT_425858].  
All IRB/IEC  approvals should be signed by [CONTACT_1201]/IEC  chairman or designee and must 
identify the  IRB/IEC  name [CONTACT_3816]; the clinical protocol by [CONTACT_60733] , or protocol number, or 
both; and the date approval or a favorable opi[INVESTIGATOR_11744]. 
The Investigator is respo nsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1  year or otherwise specified by [CONTACT_1201]/IEC . The 
Investigator must promptly supply the Sponsor or its designee , the IRB/IEC , and, where 
applicable, t he institution,  with written reports on any changes significantly affecting the 
conduct of the study or increasing the risk to patient s. 
 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their orig in in 
the Declaration of Helsinki, ICH GCP , and all applicable regulations. 
 Patient  Information and Consent  
A written informed consent in compliance with US Title 21 Code of Federal Regulations 
(CFR) Part 50 shall be obtained from each patient  before enter ing the study or performing 
any unusual or nonroutine procedure that involves risk to the patient . An informed consent 
template may be provided by [CONTACT_209804] . If any institution -specific 
modifications to study -related procedures are proposed or made by [CONTACT_3452], the consent 
should be reviewed by [CONTACT_1034], its designee , or both before IRB/IEC  submission . Once 
reviewed, the consent will be submitted by [CONTACT_425859]/IEC  for review 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538035] sign the revised form. 
Before recruitment and enrollment, each prospective patient  or his or her legal guardian will 
be given a full explanation of the study and be allowed to read the approved ICF. Once the 
Investigator is assured that the patient /legal guardian understands the implications of 
participating in the study, the  patient /legal guardian will be asked to give consent to 
participate in the study by [CONTACT_12568].  
The Investigator shall retain the signed original ICF(s) and give a copy of the signed original 
form to the patient  or legal guardian. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 101 9 Investigator ’s Obli gations 
The following administrative items are meant to guide the Investigator in the conduct of the 
study but may change based on industry and government standard operating procedures, 
working practice documents, or guidelines. Changes will be reported to the IRB/IEC  and will 
not result in protocol amendments. 
 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain patient  confidentiality . All records will be kept in a secur e 
storage area with limited access . Clinical information will not be released without the written 
permission of the patient  (or the patient ’s legal guardian), except as necessary for monitoring 
and auditing by [CONTACT_1034], its designee, the US FDA, or the  IRB/IEC . 
The Investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confi dential information to other parties.  
 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the Sponsor to submit the complete and accurate certification or disclosure s tatements required under  
[ADDRESS_538036] provide to the Sponsor a commitment to 
promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. 
Neither the Sp onsor nor the CRO  is financially responsible for further testing or treatment of 
any medical condition that may be detected during the screening process . In addition, in the 
absence of specific arrangements, neither the Sponsor nor the CRO  is financially r esponsible 
for further treatment of the patient ’s disease.  
 Investigator Documentation 
Prior to beginning the study, the Investigator will be asked to comply with ICH E6(R1) 8.2 
and Title 21 of the CFR by [CONTACT_44074], including but not 
limited to:  
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 102 •  IRB/IEC  approval 
• Original Investigator-signed Investigator agreement page of the protocol 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 
1572 
• Curriculum vitae for the Investigator and each sub- investigator listed on Form 
FDA  1572 
• Financial disclosure information to allow the Sponsor to submit complete and accurate certification or disclosure statements required under [ADDRESS_538037] provide to the Sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and 
for 1  year after study completion . 
•  IRB/IEC -approved informed consent, samples of study site advertisements for 
recruitment for t his study, and any other written information regarding this study that 
is to be provided to the patient  or legal guardian, and 
• Laboratory certifications and normal ranges for any local laboratories used by [CONTACT_112769], in accordance with [ADDRESS_538038] 
The Investigator agrees that the study will be conducted according to the principles of 
ICH E6(R1). The Investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations. Study information from this protocol will be 
posted on publicly available clinical trial registries  before enrollment of patient s begins. 
 Adherence to Protocol  
The Investigator agrees to conduct the study as outlined in this protocol in accordance with 
ICH E6(R1) and all applicable guidelines and regulations. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 103 
 Adverse Events  and Study Report Requirements  
By [CONTACT_4907] , the Investigator agrees to submit reports of SAEs  according to 
the timeline and method outlined in the protocol. In addition, the Investigator agrees to 
submit annual reports to the study site  IRB/IEC , as appropriate.  
 Investigator’s Final Report 
Upon completion of the study, the Investigator, where applicable, should inform the institution; the Investigator/institution should provide the IRB/IEC with a summary of the 
study’s outcome and the Sponsor and regulatory authority(ies) with any required reports. 
 Records Retention  
Essential documents should be retained until at least [ADDRESS_538039]. These documents 
should be retained for a longer period, however, if required by [CONTACT_67836]. It is the responsibility of the Sponsor to 
inform the Investigator/institution as to when these documents no longer need to be retained. 
 Publications  
After completion of the study, the data may be considered for reporting at a scientific meeting o r for publication in a scientific journal. In these cases, the Sponsor will be 
responsible for these activities and will work with the Investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. The Sponsor has final approval authority over all 
such issues.  
Data are the property of the Sponsor and cannot be published without prior authorization 
from the Sponsor, but data and publication thereof will not be unduly withheld. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538040] operating procedures. 
10.1.3  Inspection of Records  
Investigators and institutions involved in the study will permit study-related monitoring, 
audits, IRB/IEC  review, and regulatory inspections by [CONTACT_21766] . In the event of an audit, the Investigator agrees to allow the Sponsor , representatives 
of the Sponsor, or a regulatory agency (eg, FDA or other regulatory agency) access to all 
study records. 
The Investigator should promptly notify the Sponsor and the CRO  of any audits scheduled by 
[CONTACT_11781][INVESTIGATOR_356994]. 
 Management of Protocol Amendments and Deviations 
10.2.[ADDRESS_538041] be reviewed and approved by [CONTACT_425860] -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538042] be submitted in writing to the Investigator’s 
IRB/IEC  for approval before patient s can be enrolled into an amended protocol. 
10.2.[ADDRESS_538043] document and explain in the patient ’s source 
documentation any deviation from the approved protocol. The Investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
patie nts without prior IRB/IEC  approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments should be submitted to the IRB/IEC  for review and approval, to the Sponsor for a greement, 
and to the regulatory authorities, if required. 
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by [CONTACT_1035]/IEC  and agreed to by [CONTACT_3786]. A significant deviation  occurs when there is nonadherence to the protocol by [CONTACT_425861] a significant,  additional risk to the patient . Significant 
deviations can include nonadherence to  inclusion or exclusion criteria , enrollment of the 
patient without prior Sponsor approval, or nonadherence to FDA regulations or ICH GCP 
guidelines, and will lead to the patient  being withdrawn from the study (Section 4.2). 
Protocol deviations will be documented by [CONTACT_135786] . Principal Investigator s will be notified in writing by [CONTACT_21769]. The IRB/IEC  should be notified of all protocol deviations in a timely manner. 
 Premature Termination  or Suspension of Study  
This study may be suspended or prematurely terminated by [CONTACT_1034]. Written notification, 
documenting the reason for study suspension or termination, will be provided by [CONTACT_425862], and regulatory authorities. If the study is 
prematurely terminated or suspended, the Investigator will promptly inform the IRB/IEC  and 
will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination include, but are not limited to: 
• Determination of unexpected, significant, or unacceptable risk to patients; 
• Insufficient adherence to protocol requirements; 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 106 • Data that are not  sufficiently complete and/or evaluable; 
• Determination of futility.  
 Halting Rules  
Individual patient participation in the study may be stopped at any time at the discretion of 
the Investigator (see Section 4.2).  Individual patient participation may also be stopped at any 
time at the request of the Sponsor. Additionally, the Sponsor may place a temporary or 
permanent suspension of enrollment at any site or for the entire study.  Reasons for stoppi[INVESTIGATOR_425809]/or enrollment include, but are not limited to, violation 
of inclusion/exclusion criteria, major protocol deviation(s), or safety concerns. 
Review of serious, unexpected, and related A Es by [CONTACT_36985]/IEC , the Sponsor, or the FDA or 
relevant local regulatory authorities may also result in suspension of further study 
interventions/administration of study product at a site.  The FDA or other local regulatory 
authorities and study Sponsor retain the authority to suspend additional enrollment and study interventions/administration of study product for a site or the entire study, as applicable. 
Although the Sponsor has every intention of completing the study, the Sponsor reserves the 
right to discontinue the study at any time for clinical or administrative reasons.  
 Final Report  
Whether the study is completed or prematurely terminated, the Sponsor will ensure that the 
clinical study reports are prepared and provided to the regulatory agencies as required by [CONTACT_13179] . The Sponsor will also ensure that the clinical study 
reports in marketing applications meet the standards of the ICH harmonised triparti te 
guideline E3: Structure and content of clinical study r eports. 
Upon completion of the clinical study report, the s tudy results will be posted on publicly 
available clinical trial registries . 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-[ADDRESS_538044]  
Barnes TR. A rating scale for drug -induced akathisia. Br J Psychiatry. 1989;154:672-6. 
Costa PTJ, McCrae RR. Revised NEO Personality Inventory (NEO- PI-R) and NEO Five -
Factor In ventory (NEO -FFI) Professional Manual. Psycholo gical Assessment Resources Inc. : 
Odessa, FL. 1992. 
Davis RE, Vanover KE, Zhou Y, et al. ITI-007 demonstrates brain occupancy at serotonin 
5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl). 2015;232(15):2863-72. 
First MB, Williams JBW, Karg RS, Spi[INVESTIGATOR_4280] . Structured Clinical Interview for DSM-5 
Disorders – Clinical Trials Version (SCID -5-CT, 2014), Arlington, VA: American 
Psychiatric Association.  
Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. 
Department of Health Education, and Welfare; 1976. 616 p. 
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I 
depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014a;171(2):160-8. 
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or 
valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014b;171(2):169-77.  
Posner K, Brown GK, Stanley B, et al. The Columbia- Suicide Severity Rating Scale: i nitial 
validity and i nternal consistency findings f rom t hree m ultisite studies w ith adolescents and 
adults. Am J Psychiatry 2011;168(12):1266-77. Sachs GS. Strategies for im proving treatment of bipolar disorder: integration of measurement 
and management. Acta Psychiatr Scand Suppl 2004;422:717. Sheehan DV, Lecrubier Y, Harnett -Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, 
Baker R, Dunbar G. The Mini International Neuropsychiatric Interview (M.I.N.I.): The 
Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry. 1998;59(suppl 20):22-33. 
Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand  
Suppl. 1970;212:11–9. Sidor MM, MacQueen GM: Antidepressants for the acute treatment of bipolar depression: a 
systematic review and meta-analysis. J Clin Psychiatry 2011;72(2):156–67. 
Intra -Cellular Therapi[INVESTIGATOR_014], Inc.   Confidential  ITI-007 
Protocol: ITI -007-402  04 September 2019  
 Page 108 Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, 
dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 
2015;232(3):605-21. 
Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions 
(CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-71. 
Svenningsson P, Greengard P . p11 (S100A10) – an inducible adaptor protein that modulates 
neuronal functions. Curr Opin  Pharmacol . 2007;7(1):27-32. 
Topp CW, Østergaard SD, Søndergaard S, et al. The WHO- 5 Well -Being In dex: a systematic 
review of the literature. Psychother Psychosom. 2015;84(3):167-76. Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the 
treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010; 196(4):266-73. 
Vázquez GH, Tondo L, Undurraga J, et al.  Overview of antidepressant treatment of bipolar 
depression. Int J Neuropsychopharmacol. 2013; 6(7):1673–85. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and 
sensitivity.  Br J Psychiatry . 1978;133:429–35. 
Young AH, Calabrese JR, Gustafsson U, et al. Quetiapi[INVESTIGATOR_425810]: combined data from four large, randomized studies. Int J Bipolar Disord. 2013;1:10.
 